Antibody specifically recognizing thymic stromal lymphopoietin and use thereof

Abstract

The present application provides antibodies, including antigen-recognition fragments, that specifically recognize thymic stromal lymphopoietin (TSLP), as well as methods for preparing and using these antibodies.

Description

[Technical Field]

[0001] Submit a sequence listing as an ASCII TEXT file The contents of the submitted ASCII TEXT text file, Sequence Listing in Computer Readable Format (CRF) (Filename: 202102022277_SEQLIST.txt, Recording Date: 2021.02.02, Size: 72KB), are incorporated herein by reference in their entirety.

[0002] This application relates to antibodies that specifically recognize thymic stromal lymphopoietin (TSLP), including pharmaceutical compositions of the TSLP antibodies, reagent kits, methods for preparing and using the same, and methods for treating diseases associated with TSLP signaling, such as inflammatory diseases. [Background technology]

[0003] Full-length thymic stromal lymphopoietin (TSLP) was first identified as a cytokine capable of inducing pre-B cell proliferation in the supernatant of mouse thymic stromal cells (Friend et al., Exp Hematol. 22(3):321, 1994). Subsequently, such a mouse protein was identified (Sims et al., J Exp Med. 2000 Sep. 4, 192(5):671-80). Subsequently, in 2001, two independent groups identified human TSLP (Quentmeier et al., Leukemia. 2001 Aug. 15(8):1286-92; Reche et al., J Immunol. 2001 Jul. 1, 167(1):336-43).

[0004] Thymic stromal lymphopoietin (TSLP) is a cytokine that signals via an isodimeric receptor consisting of the IL-7Rα subunit and TSLP-R. TSLP-R is a unique component and is homologous to the common cytokine receptor γ chain (γc) (Pandey et al., Nat. Immunol. 2000, 1(1):59-64). TSLP is produced by epithelial cells at barrier surfaces and activates DCs expressing the TSLP receptor (TSLPR) to induce functional Th2 cells (Roan F et al., J Clin Invest 2019, 129:1441-51). TSLP has also been implicated in other diseases, including autoimmune disorders and cancer (Varricchi G et al., Front Immunol 2018, 9:1595). The TSLP receptor (TSLPR) complex consists of TSLPR and IL-7 receptor alpha (IL-7Rα) (Park LS, et al., J ExpMed 2000, 192:659-670). The combination of the TSLPR and IL-7R chains results in signal transduction and high-affinity binding and activation of STAT3 and STAT5 (Pandey A, et al., Nat Immunol 2000, 1:59-64). These broad pathophysiological features have prompted therapeutic targeting of TSLP- and TSLPR-mediated signaling in type 2 cytokine-mediated allergic diseases. AMG157, a fully human antibody against TSLP (used as a control in the examples), was developed by Amgen and is used to treat asthma and allergic dermatitis. This antibody is described in U.S. Patent No. 7982016.

[0005] All publications, patents, patent applications, and the disclosures of the disclosed patent applications mentioned in this application are hereby incorporated by reference in their entirety. Summary of the Invention [Means for solving the problem]

[0006] In one aspect, the present application provides an isolated anti-TSLP antibody capable of specifically binding to human and / or cynomolgus monkey TSLP. In some examples, the isolated anti-TSLP antibody comprises a heavy chain variable domain (V) comprising a heavy chain complementarity-determining region (HC-CDR) 1 comprising SGYGWS (SEQ ID NO: 1), a HC-CDR2 comprising YX1SYYGSX2SYNPSLKS (SEQ ID NO: 103), where X1 is I or F and X2 is I or T, and a HC-CDR3 comprising TNLLYFX1X2 (SEQ ID NO: 104), where X1 is D or E and X2 is S or Y. H and a light chain variable domain (V) comprising a light chain complementarity determining region (LC-CDR) 1 comprising RASQX1X2SX3X4LA (SEQ ID NO: 105) (wherein X1 is G or S, X2 is V or I, X3 is N or S, and X4 is N or Y), a LC-CDR2 comprising DX1SX2X3X4X5 (SEQ ID NO: 106) (wherein X1 is A or T, X2 is S or N, X2 is S or N, X4 is A or Q, and X5 is T or S), and a LC-CDR3 comprising QQYSX1WPX2YX3 (SEQ ID NO: 107) (wherein X1 is D or N, X2 is Q or E, and X3 is T or S). L ) and,

[0007] In some embodiments, a V includes an HC-CDR1 having an amino acid sequence set forth in SEQ ID NO: 1 or a variant thereof containing up to about three amino acid substitutions, an HC-CDR2 having an amino acid sequence set forth in any of SEQ ID NOs: 7-9 or a variant thereof containing up to about three amino acid substitutions, and an HC-CDR3 having an amino acid sequence set forth in any of SEQ ID NOs: 16-18 or a variant thereof containing up to about three amino acid substitutions. Hand an LC-CDR1 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 25 to 28 or a variant thereof containing up to about three amino acid substitutions; an LC-CDR2 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 39 to 41 or a variant thereof containing up to about three amino acid substitutions; and an LC-CDR3 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 50 to 53 or a variant thereof containing up to about three amino acid substitutions. L and an isolated anti-TSLP antibody comprising:

[0008] In some embodiments, V is selected from the group consisting of the amino acid sequences of SEQ ID NOs: 65 to 72. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V represented by any one of the amino acid sequences of SEQ ID NOs: 84 to 90. L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and an isolated anti-TSLP antibody comprising:

[0009] In some embodiments, (i) V as set forth in the amino acid sequence SEQ ID NO:65 H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:84. L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and (ii) V, as shown in the amino acid sequence SEQ ID NO:65. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:85 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and (iii) V, as shown in the amino acid sequence SEQ ID NO:66. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained inH and V, as shown in the amino acid sequence SEQ ID NO:84. L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and (iv) V, as shown in the amino acid sequence SEQ ID NO:66. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:85 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and (v) V, as shown in the amino acid sequence SEQ ID NO:67. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:84. L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and (vi) V, as shown in the amino acid sequence SEQ ID NO:67. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:85 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and (vii) V, as shown in the amino acid sequence SEQ ID NO:68. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:84. L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and (viii) V, which has the amino acid sequence SEQ ID NO:68. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:85 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in Land (ix) V as shown in the amino acid sequence SEQ ID NO:69. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:86 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and (x) V as shown in the amino acid sequence SEQ ID NO:70. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:87 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and (xi) V as shown in the amino acid sequence SEQ ID NO:69. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:88 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and (xii) V as shown in the amino acid sequence SEQ ID NO:71. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:89 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and (xiii) V as shown in the amino acid sequence SEQ ID NO:72. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:90 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and an isolated anti-TSLP antibody comprising:

[0010] In some embodiments, (i) a V CDR1 comprising an HC-CDR1 having the amino acid sequence SEQ ID NO:1, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:7, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:16. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:25, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:39, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:50. L or the V containing up to about five amino acid substitutions in its LC-CDRs. L and (ii) a V comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:1, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:8, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:16. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V variant comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:25, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:39, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:51. L or the V containing up to about five amino acid substitutions in its LC-CDRs. L and (iii) a V comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:1, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:8, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:17. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:26, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:40, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:52. L or the V containing up to about five amino acid substitutions in its LC-CDRs. Land (iv) a V comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:1, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:8, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:16. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:27, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:41, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:52. L or the V containing up to about five amino acid substitutions in its LC-CDRs. L and (v) a variant of V comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:1, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:9, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:16. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:28, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:39, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:52. L or the V containing up to about five amino acid substitutions in its LC-CDRs. L or (vi) a variant of V comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:1, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:8, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:18. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:27, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:39, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:53. L or the V containing up to about five amino acid substitutions in its LC-CDRs. L and isolated anti-TSLP antibodies comprising:

[0011] In some embodiments, like any of the isolated anti-TSLP antibodies described above, the isolated anti-TSLP antibody comprises a V antibody comprising an amino acid sequence set forth in any of SEQ ID NOs: 65-72. H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to any of the amino acid sequences of SEQ ID NOs: 65 to 72. H and a V having an amino acid sequence represented by any one of SEQ ID NOs: 84 to 90. L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to any of the amino acid sequences of SEQ ID NOs: 84 to 90. L In some embodiments, the isolated anti-TSLP antibody comprises (i) a variant of V comprising the amino acid sequence SEQ ID NO:65. H and V comprising the amino acid sequence SEQ ID NO:84 L and (ii) V comprising the amino acid sequence SEQ ID NO:65. H and V comprising the amino acid sequence SEQ ID NO:85 L and (iii) V comprising the amino acid sequence SEQ ID NO:66. H and V comprising the amino acid sequence SEQ ID NO:84 L and (iv) V comprising the amino acid sequence SEQ ID NO:66. H and V comprising the amino acid sequence SEQ ID NO:85 L and (v) V comprising the amino acid sequence SEQ ID NO:67. H and V comprising the amino acid sequence SEQ ID NO:84 L and (vi) V comprising the amino acid sequence SEQ ID NO:67. H and V comprising the amino acid sequence SEQ ID NO:85 L and (vii) V comprising the amino acid sequence SEQ ID NO:68. H and V comprising the amino acid sequence SEQ ID NO:84L and (viii) V comprising the amino acid sequence SEQ ID NO:68. H and V comprising the amino acid sequence SEQ ID NO:85 L and (ix) V comprising the amino acid sequence SEQ ID NO:69. H and V comprising the amino acid sequence SEQ ID NO:86 L and (x) V comprising the amino acid sequence SEQ ID NO:70. H and V comprising the amino acid sequence SEQ ID NO:87 L and (xi) V comprising the amino acid sequence SEQ ID NO:69. H and V comprising the amino acid sequence SEQ ID NO:88 L and (xii) V comprising the amino acid sequence SEQ ID NO:71. H and V comprising the amino acid sequence SEQ ID NO:89 L and (xiii) V comprising the amino acid sequence SEQ ID NO:72. H and V comprising the amino acid sequence SEQ ID NO:90 L and,

[0012] In one embodiment, the present application provides a heavy chain variable domain (V) comprising a heavy chain complementarity determining region (HC-CDR) 1 comprising SYGIX1 (SEQ ID NO: 108) (wherein X1 is N or S), a HC-CDR2 comprising VIX1PLX2X3VX4X5YAEKFQG (SEQ ID NO: 109) (wherein X1 is V or I, X2 is V or L, X3 is G or D, X4 is T or P, and X5 is I or N), and a HC-CDR3 comprising GX1EYFYWYFDL (SEQ ID NO: 110) (wherein X1 is Q or A). HX1 is S or T, X2 is S or T, X3 is S, T, I or N, and X4 is N or D; and X1 is S, T, I or N; X2 is S, T, I or N; X3 is S, T, I or N; ... X1 is S or T, X2 is G or S, X3 is T or G, X4 is D or H, X5 is T or I, X6 is I, G, V, or A, and X7 is L, I, or F), and a light chain variable domain (V) comprising an LC-CDR3 (wherein X1 is S or T, X2 is G or S, X3 is T or G, X4 is D or H, X5 is T or I, X6 is I, G, V, or A, and X7 is L, I, or F). L ) and an isolated anti-TSLP antibody capable of specifically binding to human and / or cynomolgus monkey TSLP, comprising:

[0013] In some embodiments, the V antibody comprises an HC-CDR1 having an amino acid sequence set forth in any of SEQ ID NOs: 2-3 or a variant thereof having up to about three amino acid substitutions, an HC-CDR2 having an amino acid sequence set forth in any of SEQ ID NOs: 10-12 or a variant thereof having up to about three amino acid substitutions, and an HC-CDR3 having an amino acid sequence set forth in any of SEQ ID NOs: 19-20 or a variant thereof having up to about three amino acid substitutions. H and V comprising an LC-CDR1 having an amino acid sequence set forth in any one of SEQ ID NOs: 29 to 34 or a variant thereof having up to about three amino acid substitutions, an LC-CDR2 having an amino acid sequence set forth in any one of SEQ ID NOs: 42 to 47 or a variant thereof having up to about three amino acid substitutions, and an LC-CDR3 having an amino acid sequence set forth in any one of SEQ ID NOs: 54 to 60 or a variant thereof having up to about three amino acid substitutions. L and an isolated anti-TSLP antibody comprising:

[0014] In some embodiments, V is selected from the group consisting of the amino acid sequences of SEQ ID NOs: 73 to 78. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V represented by any one of the amino acid sequences of SEQ ID NOs: 91 to 97. L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and an isolated anti-TSLP antibody comprising:

[0015] In some embodiments, (i) the V H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:91. L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and (ii) V, as shown in the amino acid sequence SEQ ID NO:74. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:91. L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and (iii) V, as shown in the amino acid sequence SEQ ID NO:75. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:91. L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and (iv) V, as shown in the amino acid sequence SEQ ID NO:73. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:92 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in Land (v) V, as shown in the amino acid sequence SEQ ID NO:73. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:93 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and (vi) V, as shown in the amino acid sequence SEQ ID NO:73. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:94 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and (vii) V, as shown in the amino acid sequence SEQ ID NO:76. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:95 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and (viii) V, which has the amino acid sequence SEQ ID NO:77. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:96 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and (ix) V as shown in the amino acid sequence SEQ ID NO:78. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:97 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and an isolated anti-TSLP antibody comprising:

[0016] In some embodiments, (i) a V CDR1 comprising an HC-CDR1 having the amino acid sequence SEQ ID NO:2, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:10, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:19. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:29, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:42, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:54. L or the V containing up to about five amino acid substitutions in its LC-CDRs. L and (ii) a V comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:2, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:10, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:19. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a variant of V L includes: an LC-CDR1 comprising the amino acid sequence SEQ ID NO: 30, an LC-CDR2 comprising the amino acid sequence SEQ ID NO: 43, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO: 55. L or the V containing up to about five amino acid substitutions in its LC-CDRs. L and (iii) a V comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:2, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:10, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:19. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V variant comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:31, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:44, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:56. L or the V containing up to about five amino acid substitutions in its LC-CDRs. Land (iv) a V comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:2, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:10, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:19. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO: 32, an LC-CDR2 comprising the amino acid sequence SEQ ID NO: 45, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO: 57. L or the V containing up to about five amino acid substitutions in its LC-CDRs. L and (v) a variant of V comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:3, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:11, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:19. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO: 33, an LC-CDR2 comprising the amino acid sequence SEQ ID NO: 45, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO: 58. L or the V containing up to about five amino acid substitutions in its LC-CDRs. L and (vi) a V comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:3, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:10, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:19. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:31, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:46, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:59. L or the V containing up to about five amino acid substitutions in its LC-CDRs. Lor (vii) a variant of V comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:3, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:12, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:20. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:34, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:47, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:60. L or the V containing up to about five amino acid substitutions in its LC-CDRs. L and isolated anti-TSLP antibodies comprising:

[0017] In some embodiments, like any of the isolated anti-TSLP antibodies described above, the isolated anti-TSLP antibody comprises a V antibody comprising an amino acid sequence set forth in any of SEQ ID NOs:73-78. H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to any of the amino acid sequences of SEQ ID NOs: 73 to 78. H and a V having an amino acid sequence represented by any of SEQ ID NOs: 91 to 97. L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to any of the amino acid sequences of SEQ ID NOs: 91 to 97. L In some embodiments, the isolated anti-TSLP antibody comprises (i) a variant of V comprising the amino acid sequence SEQ ID NO:73. H and V comprising the amino acid sequence SEQ ID NO:91 L and (ii) V comprising the amino acid sequence SEQ ID NO:74. H and V comprising the amino acid sequence SEQ ID NO:91 L and (iii) V comprising the amino acid sequence SEQ ID NO:75.H and V comprising the amino acid sequence SEQ ID NO:91 L and (iv) V comprising the amino acid sequence SEQ ID NO:73. H and V comprising the amino acid sequence SEQ ID NO:92 L and (v) V comprising the amino acid sequence SEQ ID NO:73. H and V comprising the amino acid sequence SEQ ID NO:93 L and (vi) V comprising the amino acid sequence SEQ ID NO:73. H and V comprising the amino acid sequence SEQ ID NO:94 L and (vii) V comprising the amino acid sequence SEQ ID NO:76. H and V comprising the amino acid sequence SEQ ID NO:95 L and (viii) V comprising the amino acid sequence SEQ ID NO:77. H and V comprising the amino acid sequence SEQ ID NO:96 L and (ix) V comprising the amino acid sequence SEQ ID NO:78. H and V comprising the amino acid sequence SEQ ID NO:97 L and,

[0018] In one embodiment, the present application provides a heavy chain variable domain (V) comprising a heavy chain complementarity determining region (HC-CDR) 1 comprising NYX1MT (SEQ ID NO: 114), where X1 is D or G, a HC-CDR2 comprising SITFASSYIYYADSVKG (SEQ ID NO: 13), and a HC-CDR3 comprising GGGAYX1GGSLDV (SEQ ID NO: 115), where X1 is H or Y. H a light chain variable domain (V) comprising a light chain complementarity determining region (LC-CDR) 1 comprising RSSQSLLHX1X2X3YTYLH (SEQ ID NO: 116) (wherein X1 is I or S, X2 is N or Y, and X3 is G or E), a LC-CDR2 comprising LVSX1RAS (SEQ ID NO: 117) (wherein X1 is H or Y), and a LC-CDR3 comprising EQTLQTPX1X2 (SEQ ID NO: 118) (wherein X1 is Y or F, and X2 is S or T).L ) and an isolated anti-TSLP antibody capable of specifically binding to human and / or cynomolgus monkey TSLP, comprising:

[0019] In some embodiments, the V includes an HC-CDR1 having an amino acid sequence set forth in any of SEQ ID NOs: 4-5 or a variant thereof having up to about three amino acid substitutions, an HC-CDR2 having an amino acid sequence set forth in any of SEQ ID NOs: 13 or a variant thereof having up to about three amino acid substitutions, and an HC-CDR3 having an amino acid sequence set forth in any of SEQ ID NOs: 21-22 or a variant thereof having up to about three amino acid substitutions. H and V comprising an LC-CDR1 having an amino acid sequence set forth in any one of SEQ ID NOs: 35 to 37 or a variant thereof having up to about three amino acid substitutions, an LC-CDR2 having an amino acid sequence set forth in any one of SEQ ID NOs: 48 to 49 or a variant thereof having up to about three amino acid substitutions, and an LC-CDR3 having an amino acid sequence set forth in any one of SEQ ID NOs: 61 to 63 or a variant thereof having up to about three amino acid substitutions. L and an isolated anti-TSLP antibody comprising:

[0020] In some embodiments, V is selected from the group consisting of the amino acid sequences of SEQ ID NOs: 79 to 81. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V represented by any one of the amino acid sequences of SEQ ID NOs: 98 to 100. L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and an isolated anti-TSLP antibody comprising:

[0021] In some embodiments, (i) V as set forth in the amino acid sequence SEQ ID NO:79 H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:98L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and (ii) V, as shown in the amino acid sequence SEQ ID NO:80. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:99 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and (iii) V as shown in the amino acid sequence SEQ ID NO:81. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO: 100. L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and an isolated anti-TSLP antibody comprising:

[0022] In some embodiments, (i) a V CDR1 comprising an HC-CDR1 having the amino acid sequence SEQ ID NO:4, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:13, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:21. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO: 35, an LC-CDR2 comprising the amino acid sequence SEQ ID NO: 48, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO: 61. L or the V containing up to about five amino acid substitutions in its LC-CDRs. L and (ii) a V comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:4, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:13, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:22. H or the V containing up to about five amino acid substitutions in its HC-CDRs. Hand a V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO: 36, an LC-CDR2 comprising the amino acid sequence SEQ ID NO: 48, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO: 62. L or the V containing up to about five amino acid substitutions in its LC-CDRs. L or (iii) a V comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:5, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:13, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:22. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:37, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:49, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:63. L or the V containing up to about five amino acid substitutions in its LC-CDRs. L and isolated anti-TSLP antibodies comprising:

[0023] In some embodiments, like any of the isolated anti-TSLP antibodies described above, the isolated anti-TSLP antibody comprises a V antibody comprising an amino acid sequence set forth in any of SEQ ID NOs:79-81. H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to any of the amino acid sequences of SEQ ID NOs: 79 to 81. H and a V having an amino acid sequence represented by any of SEQ ID NOs: 98 to 100. L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity with any of the amino acid sequences of SEQ ID NOs: 98 to 100. LIn some embodiments, the isolated anti-TSLP antibody comprises (i) a variant of V comprising the amino acid sequence SEQ ID NO:79. H and V comprising the amino acid sequence SEQ ID NO:98 L and (ii) V comprising the amino acid sequence SEQ ID NO:80. H and V comprising the amino acid sequence SEQ ID NO:99 L and (iii) V comprising the amino acid sequence SEQ ID NO:81. H and V comprising the amino acid sequence SEQ ID NO: 100 L and,

[0024] In one embodiment, the present application provides a heavy chain variable domain (V) comprising a heavy chain complementarity determining region (HC-CDR) 1 comprising SYAIS (SEQ ID NO: 6), a HC-CDR2 comprising MX1X2PLLGVTX3YAEKFQG (SEQ ID NO: 119) (wherein X1 is L or I, X2 is V or I, and X3 is N or D), and a HC-CDR3 comprising GGX1NYLYWYFDL (SEQ ID NO: 120) (wherein X1 is S or T). H ), a light chain complementarity-determining region (LC-CDR) 1 comprising TGTSSDIGGYNRX1S (SEQ ID NO: 121) (wherein X1 is V or I), a LC-CDR2 comprising X1VSKRPS (SEQ ID NO: 122) (wherein X1 is D or E), and SX1YAGTDTFV L (SEQ ID NO: 123), wherein X1 is S or A. L ) and an isolated anti-TSLP antibody capable of specifically binding to human and / or cynomolgus monkey TSLP, comprising:

[0025] In some embodiments, the V includes an HC-CDR1 having an amino acid sequence set forth in SEQ ID NO: 6 or a variant thereof comprising up to about three amino acid substitutions, an HC-CDR2 having an amino acid sequence set forth in any of SEQ ID NOs: 14-15 or a variant thereof comprising up to about three amino acid substitutions, and an HC-CDR3 having an amino acid sequence set forth in any of SEQ ID NOs: 23-24 or a variant thereof comprising up to about three amino acid substitutions. H and V comprising an LC-CDR1 comprising the amino acid sequence set forth in any of SEQ ID NOs: 31 and 38 or a variant thereof comprising up to about three amino acid substitutions, an LC-CDR2 comprising the amino acid sequence set forth in any of SEQ ID NOs: 42 and 45 or a variant thereof comprising up to about three amino acid substitutions, and an LC-CDR3 comprising the amino acid sequence set forth in any of SEQ ID NOs: 60 and 64 or a variant thereof comprising up to about three amino acid substitutions. L and an isolated anti-TSLP antibody comprising:

[0026] In some embodiments, V is selected from the group consisting of the amino acid sequences of SEQ ID NOs: 82 to 83. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V represented by any one of the amino acid sequences of SEQ ID NOs: 101 to 102. L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and an isolated anti-TSLP antibody comprising:

[0027] In some embodiments, (i) V as set forth in the amino acid sequence SEQ ID NO:82 H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO: 101. L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and (ii) V as shown in the amino acid sequence SEQ ID NO:83.H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO: 102. L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and an isolated anti-TSLP antibody comprising:

[0028] In some embodiments, (i) a V CDR1 comprising an HC-CDR1 having the amino acid sequence SEQ ID NO:6, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:14, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:23. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO: 38, an LC-CDR2 comprising the amino acid sequence SEQ ID NO: 42, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO: 60. L or the V containing up to about five amino acid substitutions in its LC-CDRs. L or (ii) a V comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:6, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:15, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:24. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:31, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:45, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:64. L or the V containing up to about five amino acid substitutions in its LC-CDRs. L and isolated anti-TSLP antibodies comprising:

[0029] In some embodiments, like any of the isolated anti-TSLP antibodies described above, the isolated anti-TSLP antibody comprises a V antibody comprising an amino acid sequence set forth in any of SEQ ID NOs:82-83. H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to any of the amino acid sequences of SEQ ID NOs: 82 to 83. H and a V having an amino acid sequence represented by any one of SEQ ID NOs: 101 to 102. L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity with any of the amino acid sequences of SEQ ID NOs: 101 to 102. L In some embodiments, the isolated anti-TSLP antibody comprises (i) a variant of V comprising the amino acid sequence SEQ ID NO:82. H and V comprising the amino acid sequence SEQ ID NO:101 L and (ii) V comprising the amino acid sequence SEQ ID NO:83. H and V comprising the amino acid sequence SEQ ID NO: 102 L and,

[0030] In some embodiments, an isolated anti-TSLP antibody that specifically binds to human TSLP has a Kd value of about 0.1 pM to about 1 nM is provided.

[0031] In some embodiments, an isolated anti-TSLP antibody is provided that competes with any of the above-described isolated anti-TSLP antibodies for specific binding to TSLP. In some embodiments, an isolated anti-TSLP antibody is provided that specifically binds to the same epitope as any of the above-described isolated anti-TSLP antibodies.

[0032] In some embodiments, the isolated anti-TSLP antibody comprises an Fc fragment, such as any of the isolated anti-TSLP antibodies described above. In some embodiments, the isolated anti-TSLP antibody is a full-length IgG antibody. In some embodiments, the isolated anti-TSLP antibody is a full-length IgG1, IgG2, IgG3, or IgG4 antibody. In some embodiments, the isolated anti-TSLP antibody is a chimeric, human, or humanized antibody. In some embodiments, the isolated anti-TSLP antibody is an antigen-binding fragment selected from a Fab, Fab', F(ab')2, Fab'-SH, single-chain Fv (scFv), Fv fragment, dAb, Fd, nanobody, double-chain antibody (diabody), and linear antibody.

[0033] In some embodiments, an isolated nucleic acid molecule encoding any of the above anti-TSLP antibodies is provided. In some embodiments, a vector comprising any of the above nucleic acid molecules is provided. In some embodiments, a host cell expressing any of the above anti-TSLP antibodies, any of the above nucleic acid molecules, or any of the above vectors is provided. In some embodiments, a method for preparing an anti-TSLP antibody is provided, comprising: a) culturing any of the above host cells under conditions allowing effective expression of the anti-TSLP antibody; and b) obtaining the expressed anti-TSLP antibody from the host cell. In some embodiments, a pharmaceutical composition is provided comprising the above isolated anti-TSLP antibody, nucleic acid, vector, or isolated host cell, and a pharmaceutically acceptable vector.

[0034] In some embodiments, methods are provided for treating a disease or condition in an individual in need thereof, comprising administering to the individual an effective amount of any of the anti-TSLP antibodies or pharmaceutical compositions provided herein. In some embodiments, the use of any of the anti-TSLP antibodies provided herein in treating a disease or condition is provided. In some embodiments, the use of any of the anti-TSLP antibodies provided herein in preparing a pharmaceutical composition for treating a disease or condition in an individual in need thereof is provided. In some embodiments, the use of an anti-TSLP antibody or pharmaceutical composition provided herein in the manufacture of a medicament for treating a disease or condition is provided. In some embodiments, the disease or condition is associated with TSLP and includes an inflammatory or autoimmune disease or condition. In some embodiments, the disease or condition is selected from the group consisting of asthma, chronic obstructive pulmonary disease, allergic rhinitis, allergic sinusitis, allergic conjunctivitis, eosinophilic esophagitis, and atopic dermatitis.

[0035] Additionally, pharmaceutical compositions, reagent kits, and articles of manufacture containing any of the above anti-TSLP antibodies are also provided. [Brief explanation of the drawings]

[0036] [Figure 1A] The results shown in Figures 1A-1F are the binding affinities of exemplary anti-TSLP antibodies to human TSLP as analyzed by ELISA. [Figure 1B] The results shown in Figures 1A-1F are the binding affinities of exemplary anti-TSLP antibodies to human TSLP as analyzed by ELISA. [Figure 1C] The results shown in Figures 1A-1F are the binding affinities of exemplary anti-TSLP antibodies to human TSLP as analyzed by ELISA. [Figure 1D] The results shown in Figures 1A-1F are the binding affinities of exemplary anti-TSLP antibodies to human TSLP as analyzed by ELISA. [Figure 1E] The results shown in Figures 1A-1F are the binding affinities of exemplary anti-TSLP antibodies to human TSLP as analyzed by ELISA. [Figure 1F] The results shown in Figures 1A-1F are the binding affinities of exemplary anti-TSLP antibodies to human TSLP as analyzed by ELISA. [Figure 2A] The results shown in Figures 2A-2F are the binding affinities of exemplary anti-TSLP antibodies to cynomolgus monkey TSLP as analyzed by ELISA. [Figure 2B] The results shown in Figures 2A-2F are the binding affinities of exemplary anti-TSLP antibodies to cynomolgus monkey TSLP as analyzed by ELISA. [Figure 2C] The results shown in Figures 2A-2F are the binding affinities of exemplary anti-TSLP antibodies to cynomolgus monkey TSLP as analyzed by ELISA. [Figure 2D] The results shown in Figures 2A-2F are the binding affinities of exemplary anti-TSLP antibodies to cynomolgus monkey TSLP as analyzed by ELISA. [Figure 2E] The results shown in Figures 2A-2F are the binding affinities of exemplary anti-TSLP antibodies to cynomolgus monkey TSLP as analyzed by ELISA. [Figure 2F] The results shown in Figures 2A-2F are the binding affinities of exemplary anti-TSLP antibodies to cynomolgus monkey TSLP as analyzed by ELISA. [Figure 3A] The results shown in Figure 3A are the affinity Kd of the detected anti-TSLP antibodies TSLP-0107 or TSLP-0202 to human TSLP. [Figure 3B] The results shown in Figure 3B are the affinity Kd of the detected anti-TSLP antibodies TSLP-0107 and TSLP-0202 to cynomolgus monkey TSLP. [Figure 4] The results shown in Figure 4 are the cross-reactivity of an exemplary anti-TSLP antibody with the homologous protein IL-7 as analyzed by ELISA. [Figure 5A] The results shown in Figure 5A demonstrate that rabbit anti-TSLP polyclonal antibodies can bind to human short-form TSLP. [Figure 5B]The results shown in Figure 5B demonstrate that rabbit anti-TSLP polyclonal antibodies can bind to human full-length TSLP. [Figure 5C] The results shown in Figure 5C demonstrate that the anti-TSLP antibody TSLP-01 cannot bind to human short-form TSLP. [Figure 5D] The results shown in Figure 5D demonstrate that the anti-TSLP antibody TSLP-01 cannot bind to human full-length TSLP. [Figure 6] The results shown in Figure 6 demonstrate the inhibition of TARC release by exemplary anti-TSLP antibodies in human PBMCs. [Figure 7A] The results shown in Figures 7A-7D are pharmacokinetic analysis results measured by ELISA after subcutaneous injection of 30 mg / kg or 10 mg / kg of different antibodies or exemplary anti-TSLP antibodies into rats. Figure 7A shows the pharmacokinetic results after subcutaneous injection of 30 mg / kg of the anti-TSLP antibodies TSLP-0107 or AMG157 into rats. Figure 7B shows the pharmacokinetic results after subcutaneous injection of 10 mg / kg of the anti-TSLP antibodies TSLP-0107 or AMG157 into rats. Figure 7C shows the pharmacokinetic results after subcutaneous injection of 30 mg / kg of the anti-TSLP antibodies TSLP-0202 or AMG157 into rats. Figure 7D shows the pharmacokinetic results after subcutaneous injection of 10 mg / kg of the anti-TSLP antibodies TSLP-0202 or AMG157 into rats. [Figure 7B]The results shown in Figures 7A-7D are pharmacokinetic analysis results measured by ELISA after subcutaneous injection of 30 mg / kg or 10 mg / kg of different antibodies or exemplary anti-TSLP antibodies into rats. Figure 7A shows the pharmacokinetic results after subcutaneous injection of 30 mg / kg of the anti-TSLP antibodies TSLP-0107 or AMG157 into rats. Figure 7B shows the pharmacokinetic results after subcutaneous injection of 10 mg / kg of the anti-TSLP antibodies TSLP-0107 or AMG157 into rats. Figure 7C shows the pharmacokinetic results after subcutaneous injection of 30 mg / kg of the anti-TSLP antibodies TSLP-0202 or AMG157 into rats. Figure 7D shows the pharmacokinetic results after subcutaneous injection of 10 mg / kg of the anti-TSLP antibodies TSLP-0202 or AMG157 into rats. [Figure 7C] The results shown in Figures 7A-7D are pharmacokinetic analysis results measured by ELISA after subcutaneous injection of 30 mg / kg or 10 mg / kg of different antibodies or exemplary anti-TSLP antibodies into rats. Figure 7A shows the pharmacokinetic results after subcutaneous injection of 30 mg / kg of the anti-TSLP antibodies TSLP-0107 or AMG157 into rats. Figure 7B shows the pharmacokinetic results after subcutaneous injection of 10 mg / kg of the anti-TSLP antibodies TSLP-0107 or AMG157 into rats. Figure 7C shows the pharmacokinetic results after subcutaneous injection of 30 mg / kg of the anti-TSLP antibodies TSLP-0202 or AMG157 into rats. Figure 7D shows the pharmacokinetic results after subcutaneous injection of 10 mg / kg of the anti-TSLP antibodies TSLP-0202 or AMG157 into rats. [Figure 7D]The results shown in Figures 7A-7D are pharmacokinetic analysis results measured by ELISA after subcutaneous injection of 30 mg / kg or 10 mg / kg of different antibodies or exemplary anti-TSLP antibodies into rats. Figure 7A shows the pharmacokinetic results after subcutaneous injection of 30 mg / kg of the anti-TSLP antibodies TSLP-0107 or AMG157 into rats. Figure 7B shows the pharmacokinetic results after subcutaneous injection of 10 mg / kg of the anti-TSLP antibodies TSLP-0107 or AMG157 into rats. Figure 7C shows the pharmacokinetic results after subcutaneous injection of 30 mg / kg of the anti-TSLP antibodies TSLP-0202 or AMG157 into rats. Figure 7D shows the pharmacokinetic results after subcutaneous injection of 10 mg / kg of the anti-TSLP antibodies TSLP-0202 or AMG157 into rats. DETAILED DESCRIPTION OF THE INVENTION

[0037] One aspect of the present application provides isolated anti-TSLP antibodies capable of specifically binding to human and / or cynomolgus monkey TSLP. Through a combination of scFv phage library selection, affinity maturation, and appropriately designed biochemical and biological assays, the present invention has identified efficient antibody molecules capable of binding to human and / or cynomolgus monkey TSLP and inhibiting the action of human and / or cynomolgus monkey TSLP and its receptor. The results presented herein demonstrate that, in various biological assays, the antibodies of the present application have higher affinity for binding to human and / or cynomolgus monkey TSLP than the known anti-TSLP antibody AMG157 (Amgen), and surprisingly, are more effective than AMG157.

[0038] Anti-TSLP antibodies of the present application include, for example, full-length anti-TSLP antibodies, anti-TSLP single-chain antibodies (scFvs), anti-TSLP Fc fusion proteins, multispecific (e.g., bispecific) anti-TSLP antibodies, anti-TSLP immune complexes, and the like.

[0039] Additionally provided are nucleic acids encoding anti-TSLP antibodies, compositions comprising anti-TSLP antibodies, and methods for preparing and using the anti-TSLP antibodies of the present application.

[0040] definition As used herein, "treatment" or "treating" refers to a method of obtaining beneficial or desired results, including clinical outcomes. For purposes of this application, beneficial or desired clinical outcomes include, but are not limited to, one or more of: alleviating one or more symptoms attributable to a disease, reducing the extent of the disease, stabilizing the disease (e.g., preventing or slowing the progression of the disease), preventing or slowing the spread of the disease (e.g., metastasis), preventing or slowing the recurrence of the disease, slowing or alleviating the progression of the disease, ameliorating the disease state, alleviating the disease (in part or in whole), reducing the dose of one or more other drugs required to treat the disease, slowing the progression of the disease, improving or enhancing quality of life, increasing weight, and / or increasing survival. At the same time, "treatment" also includes reducing the pathological consequences of the disease (e.g., tumor volume in the case of cancer). The methods of this application contemplate any one or more of these treatments.

[0041] The term "antibody" includes full-length antibodies and antigen-binding fragments thereof. Full-length antibodies contain two heavy chains and two light chains. The variable regions of the light and heavy chains are responsible for antigen binding. The variable regions in the two chains typically contain three hypervariable loops, called complementarity-determining regions (CDRs). (Light chain (LC) CDRs contain LC-CDR1, LC-CDR2, and LC-CDR3; heavy chain (HC) CDRs contain HC-CDR1, HC-CDR2, and HC-CDR3.) The CDR boundaries of the antibodies or antigen-binding fragments disclosed herein can be defined or recognized according to the conventions of Kabat, Chothia, or Al-Lazikani (Al-Lazikani 1997; Chothia 1985; Chothia 1987; Chothia 1989; Kabat 1987; Kabat 1991). The three CDR regions of a heavy or light chain are inserted between side flap regions called framework regions (FRs), which are more conserved than the CDR regions and form a support for the hypervariable loops. The constant regions of the heavy and light chains are not involved in antigen binding but exhibit various functional functions. Antibodies are classified or categorized based on the amino acid sequence of the constant regions of their heavy chains. The five major antibody types or isotypes are IgA, IgD, IgE, IgG, and IgM, characterized by the presence of α, δ, ε, γ, and μ heavy chains, respectively. Several major antibody types are divided into subclasses: IgG1 (γ1 heavy chain), IgG2 (γ2 heavy chain), IgG3 (γ3 heavy chain), IgG4 (γ4 heavy chain), IgA1 (α1 heavy chain), or IgA2 (α2 heavy chain).

[0042] As used herein, the term "antigen-binding fragment" includes antibody fragments, such as double-chain antibodies (diabodies), Fab, Fab', F(ab'), Fv fragments, disulfide-stabilized Fv fragments (dsFv), (dsFv)2, bispecific dsFv (dsFv-dsFv'), disulfide-stabilized double-chain antibodies (ds double-chain antibodies), single-chain Fvs (scFv), scFv dimers (bivalent double-chain antibodies), multispecific antibodies composed of antibody fragments containing one or more CDRs, single-domain antibodies, nanobodies, domain antibodies, bivalent domain antibodies, or any other antibody fragment that can bind to an antigen but does not comprise a complete antibody structure. Antigen-binding fragments also include fusion proteins comprising the above-described antibody fragments. Antigen-binding fragments can bind to the same antigen as the parent antibody or parent antibody fragment (e.g., the parent scFv). In some examples, the antigen-binding fragment may comprise one or more CDRs from a particular human antibody, which CDRs are grafted onto framework regions from one or more different human antibodies.

[0043] As used herein, the term "epitope" refers to a specific atom or group of amino acids on an antibody or on an antigen to which an antibody partially binds. If two antibodies or antibody portions compete for binding to an antigen, they may bind to the same epitope on the antigen.

[0044] As described herein, a first antibody "competes" with a second antibody for binding to a TSLP target if the first antibody inhibits target binding of the second antibody to TSLP by at least 50% (e.g., at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%) at equimolar concentrations, and vice versa. PCT Publication WO 03 / 48731 describes a method for high-throughput antibody "epitope typing" based on cross-competition.

[0045] As used herein, the terms "specifically bind," "specifically recognize," or "specific for" refer to a measurable and reproducible interaction; for example, binding of an antibody to a target can confirm the presence of the target in a heterogeneous population containing biomolecules. For example, an antibody can specifically recognize a target (which may be an epitope) if the binding of the antibody to the target has higher affinity, avidity, is easier, and / or lasts longer than binding to other targets. In some examples, an antibody that specifically recognizes an antigen reacts with one or more antigenic determinants of the antigen and has a binding affinity that is at least 10 times higher than the binding affinity to other targets.

[0046] As used herein, an "isolated" anti-TSLP antibody means an anti-TSLP antibody that (1) is not associated with a naturally occurring protein, (2) is free from other proteins of the same origin, (3) is expressed by cells of a different species, or (4) does not exist in nature.

[0047] As used herein, the term "isolated nucleic acid" refers to a nucleic acid of genomic, cDNA, or synthetic origin, or a combination thereof. Based on its origin, the "isolated nucleic acid" (1) is not related to all or part of the polynucleotide of the "isolated nucleic acid" found in nature, (2) can be operably linked to a polynucleotide with which it is not naturally linked, or (3) does not occur as part of a longer sequence in nature.

[0048] TIFF0007641393000001.tif126170

[0049] [Table 1]

[0050] The term "chimeric antibody" refers to antibodies in which a portion of the heavy and / or light chain corresponds to or is homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody type or subclass, and the remainder of the chain(s) corresponds to or is homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody type or subclass, and fragments of such antibodies, provided they have biological activity as defined herein (see U.S. Patent No. 4,816,567, and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)).

[0051] An "Fv" is the smallest antibody fragment that contains a complete antigen-recognition and binding site. The fragment is a dimer formed by the tight, non-covalent association of one heavy-chain variable domain and one light-chain variable domain. The folding of these two domains derives six hypervariable loops (three loops per light chain and three loops per heavy chain), which provide the antibody with amino acid residues for antigen binding and confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv fragment containing only three antigen-specific CDRs) has the ability to recognize and bind antigen, albeit with a lower affinity than the complete binding site.

[0052] "Single-chain Fv" may be abbreviated as "sFv" or "scFv" and refers to VFvs linked in a single polypeptide chain. H and V L In some embodiments, the scFv polypeptide is an antibody fragment comprising a V H and V LThe scFv further comprises a linking polypeptide between the domains, which allows the scFv to form an ideal structure for antigen binding. For a summary of scFvs, see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).

[0053] The term "double-chain antibodies (diabodies)" refers to V H and V L It refers to small antibody fragments prepared by constructing scFv fragments (see the previous paragraph) using a short linker (e.g., 5-10 residues) between the domains, which allows inter-chain rather than intra-chain pairing of the variable domains, generating a single bivalent fragment, i.e., a fragment with two antigen-binding sites. Bispecific two-chain antibodies are isodimers of two "crossover" scFv fragments, where the V of the two antibodies H and V L The domains are located on different polypeptide chains. Double-chain antibodies are thoroughly described in EP 404,097, WO 93 / 11161, and Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993).

[0054] "Humanized" forms of non-human (e.g., rodent) antibodies are chimeric antibodies, containing minimal sequence derived from the non-human antibody. Often, humanized antibodies are human immunoglobulins (acceptor antibodies) in which hypervariable region (HVR) residues of the acceptor antibody are replaced by residues from a hypervariable region of a non-human species, such as mouse, rat, rabbit, or non-human primate, that has the desired antibody specificity, affinity, and performance (donor antibody). In some cases, residues in the framework regions (FR) of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also contain residues that are not present in either the acceptor antibody or the donor antibody. These modifications can further improve antibody performance. Humanized antibodies typically contain at least one, and usually two, variable domains, in which all or nearly all of the hypervariable loops correspond to those of a non-human immunoglobulin, and all or nearly all of the framework regions are human immunoglobulin sequences. The human antibody preferably further comprises at least a portion of an immunoglobulin constant region (Fc), typically a human immunoglobulin constant region. For specific details, see Jones et al., Nature 321:522-525 (1986), Riechmann et al., Nature 332:323-329 (1988), and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992).

[0055] The "percent amino acid sequence identity" or "homology" of the polypeptide and antibody sequences identified herein is defined as the percentage of identical amino acid residues in a candidate sequence and a target polypeptide sequence, where conservative substitutions are considered part of the sequence identity. Percent amino acid sequence identity can be determined using a variety of comparison methods within the skill of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, Megalign (DNASTAR), or MUSCLE software. Those skilled in the art will be able to determine appropriate parameters for measuring the comparison, including any algorithms necessary to maximize the comparison over the entire length of the compared sequences. However, for purposes of this specification, percent amino acid sequence identity values ​​will be generated using the sequence comparison computer program MUSCLE (Edgar, R.C., Nucleic Acids Research 32(5):1792-1797, 2004; Edgar, R.C., BMC Bioinformatics 5(1):113, 2004).

[0056] TIFF0007641393000003.tif104170

[0057] The term "FcRn" refers to the neonatal Fc receptor (FcRn). FcRn is structurally similar to the major histocompatibility complex (MHC) and is composed of an α chain noncovalently linked to β2-microglobulin. The various functions of the neonatal Fc receptor FcRn are described in Ghetie and Ward (2000) Annu. Rev. Immunol. 18, 739–766. FcRn plays an important role in the passive transfer of immunoglobulin IgGs from mother to neonate and in regulating serum IgG levels. As a marmoset IgG receptor, FcRn can bind and transport pinocytosed IgG intact within and between cells, preventing it from undergoing the default degradation pathway.

[0058] The "CH1 domain" of the Fc region of human IgG typically stretches from amino acid 118 to amino acid 215 (EU numbering system).

[0059] The "hinge region" is usually defined as stretching from Glu at position 216 to Pro at position 230 of human IgG1 (Burton, Molec. Immunol. 22:161-206 (1985)). The IgG1 sequence can be compared to the hinge regions of other IgG isotypes by placing the first and last cysteine ​​residues that form the inter-heavy chain disulfide bond in the same positions as in IgG1.

[0060] The "CH2 domain" of the Fc region of human IgG typically extends from amino acid 231 to amino acid 340. The CH2 domain is unique in that it does not tightly pair with other domains, but rather inserts two branched carbohydrate chains linked at their N-terminus between the two CH2 domains in intact native IgG molecules. It has been speculated that the carbohydrates may contribute to the stability of the CH2 domains by acting as an alternative to interdomain pairing. (Burton, Molec Immunol. 22:161-206 (1985)).

[0061] The "CH3" domain comprises the stretch from the C-terminal residue within the Fc region to the CH2 domain (from amino acid 341 to the C-terminus of the antibody sequence, usually amino acid residue 446 or 447 for IgG).

[0062] A "functional Fc fragment" has an "effect function" possessed by a native Fc region sequence. Exemplary "effect functions" include C1q binding, complement-dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cellular cytotoxicity (ADCC), phagocytosis, and degradation of cell surface receptors (e.g., B cell receptors, BCR). Such effect functions generally require binding of the Fc region to a binding domain (e.g., an antibody variable region) and can be assessed using various experimental methods known in the art.

[0063] An IgG Fc variant antibody with "altered" FcR binding affinity or ADCC activity has either enhanced or weakened FcR binding activity (e.g., FcγR or FcRn) and / or ADCC activity compared to the parent polypeptide or a polypeptide comprising the native IgG Fc sequence. Fc variants that exhibit "enhanced binding" to an FcR have a higher binding affinity (e.g., a lower apparent Kd or IC) to at least one FcR compared to the parent polypeptide or a polypeptide comprising the native IgG Fc sequence. 50 In some embodiments, the binding ability is increased by 3-fold, e.g., 5-, 10-, 25-, 50-, 60-, 100-, 150-, 200-, or even 500-fold, or the binding strength is increased by 25% to 1000% compared to the parent polypeptide. Fc variants that exhibit "reduced binding" to an FcR have a lower affinity (e.g., a higher apparent Kd or IC) for at least one FcR compared to the parent polypeptide. 50 The binding capacity is reduced by 40% or more compared to the parent polypeptide.

[0064] "Antibody-dependent cellular cytotoxicity" or "ADCC" is a form of cytotoxicity in which secreted Ig binds to Fc receptors (FcRs) present on some cytotoxic cells (e.g., natural killer cells (NK), neutrophils, and macrophages), allowing these cytotoxic effector cells to specifically bind to antigen-bearing target cells and then kill them using cytotoxins. Antibodies "arm" the cytotoxic cells, which are required for such killing. Of the major cell types mediating ADCC, NK cells express only FcγRIII, whereas monocytes express FcγRI, FcγRII, and FcγRIII. Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991), summarizes the expression of FcRs on hematopoietic cells. To assess the ADCC activity of a target molecule, in vitro ADCC experiments can be performed, as described in U.S. Patent Nos. 5,500,362 or 5,821,337. Effector cells applicable to such experiments include peripheral blood mononuclear cells (PBMCs) and natural killer cells (NK). Preferably, or in addition, the ADCC activity of a target molecule can also be assessed in vivo, as described, for example, in the animal model disclosed in Clynes et al. PNAS (USA) 95:652-656 (1998).

[0065] A polypeptide comprising an Fc region variant exhibits "enhanced ADCC activity," or the ability to mediate ADCC more effectively, in the presence of human effector cells compared to a polypeptide comprising the Fc of wild-type IgG or the parent polypeptide. When the polypeptide comprising the Fc region variant is quantitatively equivalent to a polypeptide comprising the Fc of wild-type IgG (or the parent polypeptide) in an experiment, it can mediate ADCC more effectively, both in vitro and in vivo. Typically, such variants are identified using any in vitro ADCC experimental method known in the art, e.g., using an experiment or method for identifying ADCC activity, e.g., in an animal model. In some embodiments, such variants mediate ADCC 5- to 100-fold more efficiently, e.g., 25- to 50-fold more efficiently, compared to the wild-type Fc (or parent polypeptide).

[0066] "Complement-dependent cytotoxicity" or "CDC" refers to the lysis of target cells in the presence of complement. Activation of the classical complement pathway is initiated by the binding of the first component of the complement system (C1q) to an antibody (of the appropriate structural subclass) that binds to the same antigen. To assess complement activation, CDC experiments can be performed as described in Gazzano-Santoro et al., J. Immunol. Methods 202:163 (1996). U.S. Patent No. 6,194,551 B1 and WO 99 / 51642 describe polypeptide variants with altered amino acid sequences in the Fc region that increase or decrease C1q binding capacity. The contents of these patent publications are expressly incorporated herein by reference. See also Idusogie et al., J. Immunol. 164:4178-4184 (2000).

[0067] Unless otherwise specified, a "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that encode the same amino acid sequence in a degenerate form. A nucleotide sequence encoding a protein or RNA may further include introns; for example, a nucleotide sequence encoding a protein includes introns in some forms.

[0068] The term "operably linked" refers to a functional linkage between a regulatory sequence and a heterologous nucleotide sequence to allow for expression of the heterologous nucleotide sequence. For example, a first nucleotide sequence and a second nucleotide sequence are operably linked when they are in a functional relationship. For example, a promoter and a coding sequence are operably linked if they affect the transcription or expression of the coding sequence. Usually, operably linked DNA sequences are contiguous and, where necessary, can link two protein coding regions in the same reading frame.

[0069] "Homologous" refers to the sequence similarity or sequence identity between two polypeptides or two nucleic acid molecules. If the identical positions in two compared sequences contain the same base or amino acid monomer subunit, for example, if the identical positions in two DNA molecules are both adenine, the two DNA molecules are homologous at that position. The percentage of homology between two sequences refers to the ratio of the number of matching or homologous positions shared by the two sequences to the total number of positions multiplied by 100. For example, if 6 of 10 positions in two sequences are matching or homologous, the homology between the two sequences is 60%. For example, the DNA sequences ATTGCC and TATGGC have 50% homology. Usually, when comparing two sequences, the aim is to obtain the greatest homology.

[0070] An "effective amount" of an anti-TSLP antibody or composition disclosed herein means an amount sufficient to achieve a particular purpose. An "effective amount" can be empirically determined by methods related to that purpose known in the art.

[0071] The term "therapeutically effective amount" refers to an amount of an anti-TSLP antibody or composition disclosed herein that can effectively "treat" a disease or condition in an individual. In the case of cancer, a therapeutically effective amount of an anti-TSLP antibody or composition disclosed herein can reduce the number of cancer cells, reduce tumor size and weight, inhibit (i.e., slow to a certain extent, and preferably stop) cancer cell invasion into surrounding organs, inhibit (i.e., slow to a certain extent, and preferably stop) tumor metastasis, inhibit tumor growth to a certain extent, and / or alleviate one or more symptoms associated with cancer to a certain extent. The anti-TSLP antibodies or compositions disclosed herein can be cytostatic and / or cytotoxic to the extent that they can prevent the growth and / or kill existing cancer cells. In some embodiments, a therapeutically effective amount is a growth-inhibiting amount. In some embodiments, a therapeutically effective amount is an amount that prolongs patient survival. In some embodiments, a therapeutically effective amount is an amount that improves progression-free survival in a patient.

[0072] As used herein, "pharmaceutically acceptable" or "pharmacologically acceptable" means a material that is free of biological activity or other undesirable properties, e.g., the material can be added to a pharmaceutical composition to be administered to a patient without producing a significant adverse biological response or interacting in a deleterious manner with any other ingredients included in the composition. Preferably, a pharmaceutically acceptable vector or excipient meets the required standards of toxicology and manufacturing detection and / or is included in the inactive ingredient guidelines established by the U.S. Food and Drug Administration.

[0073] It should be understood that embodiments of the present application described herein include embodiments "consisting of" and / or "consisting essentially of."

[0074] As used herein, "about" refers to a single numerical value or parameter and includes (describes) variations on that value or parameter itself. For example, a statement about "about X" includes the statement of "X."

[0075] As used herein, "not" a value or parameter generally refers to "other than" that value or parameter. For example, "the method cannot be used to treat type X cancer" means that the method is generally used to treat cancers other than type X.

[0076] As used herein and in the following claims, the singular forms "a," "one," and "the" include plural referents unless the context clearly dictates otherwise.

[0077] Anti-TSLP antibody In one embodiment, the present application provides anti-TSLP antibodies that specifically bind to human and / or cynomolgus monkey TSLP. Such anti-TSLP antibodies include, but are not limited to, humanized antibodies, chimeric antibodies, murine antibodies, human antibodies, and antibody molecules comprising the heavy and / or light chain CDRs described herein. In one embodiment, the present application provides isolated antibodies that bind to TSLP. Potential anti-TSLP antibodies include, for example, full-length anti-TSLP antibodies (e.g., full-length IgG1 or IgG4), anti-TSLP single-chain antibodies, anti-TSLP Fc fusion proteins, multispecific (e.g., bispecific) anti-TSLP antibodies, anti-TSLP immune complexes, and the like. In some examples, the anti-TSLP antibody is a full-length antibody (e.g., full-length IgG1 or IgG4) or an antigen-binding fragment thereof that specifically binds to TSLP. In some embodiments, the anti-TSLP antibody is a Fab, Fab', F(ab')2, Fab'-SH, single-chain Fv (scFv), Fv fragment, dAb, Fd, nanobody, double-chain antibody (diabody), or linear antibody. In some embodiments, an antibody that specifically binds to TSLP has a binding affinity for TSLP that is at least 10 times greater (e.g., 10, 10 2 , 10 3 , 10 4 , 10 5 , 10 6 , or 10 7In some embodiments, non-target refers to an antigen that is not TSLP. Binding affinity can be measured by methods known in the art, such as ELISA, fluorescence-activated cell sorting (FACS) analysis, or radioimmunoprecipitation (RIA). Kd values ​​can be measured by methods known in the art, such as surface plasmon resonance (SPR) technology or biolayer interferometry (BLI).

[0078] Although anti-TSLP antibodies comprising human sequences (e.g., human heavy and light chain variable domains comprising human CDR sequences) are broadly discussed herein, non-human anti-TSLP antibodies are also contemplated. In some embodiments, the non-human anti-TSLP antibodies comprise the human CDR sequences and non-human frame region sequences of an anti-TSLP antibody described herein. In some embodiments, the non-human frame region sequences include any sequences for generating heavy and / or light chain variable domains using one or more human CDR sequences described herein, including mammals such as mouse, rat, rabbit, pig, cattle (e.g., cow, ox, buffalo), deer, sheep, goat, chicken, cat, dog, mink, primates (e.g., marmoset, rhesus monkey), etc. In some embodiments, the non-human anti-TSLP antibodies include anti-TSLP antibodies generated by grafting one or more human CDR sequences described herein onto non-human frame region sequences (e.g., mouse or chicken frame region sequences).

[0079] The complete amino acid sequence of an exemplary native human TSLP comprises or consists of the amino acid sequence set forth in SEQ ID NO: 128. The amino acid sequence of an exemplary modified human TSLP comprises or consists of the amino acid sequence set forth in SEQ ID NO: 129.

[0080] In some embodiments, the anti-TSLP antibodies described herein specifically recognize an epitope in human TSLP. In some embodiments, the anti-TSLP antibodies cross-react with TSLP from species other than human. In some embodiments, the anti-TSLP antibodies are completely specific for human TSLP and do not cross-react with TSLP from other non-human species.

[0081] In some embodiments, the anti-TSLP antibody cross-reacts with at least one allelic variant of the TSLP protein (or fragment thereof). In some embodiments, the allelic variant has up to 30 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, or 30) amino acid substitutions (e.g., conservative substitutions) compared to a naturally occurring TSLP protein (or fragment thereof). In some embodiments, the anti-TSLP antibody does not cross-react with any allelic variant of the TSLP protein (or fragment thereof).

[0082] In some embodiments, the anti-TSLP antibody cross-reacts with at least one interspecies variant of the TSLP protein. In some embodiments, for example, the TSLP protein (or fragment thereof) is human TSLP and the interspecies variant of the TSLP protein (or fragment thereof) is a cynomolgus monkey variant. In some embodiments, the anti-TSLP antibody does not cross-react with any interspecies variant of the TSLP protein.

[0083] In some embodiments, the anti-TSLP antibody, like any anti-TSLP antibody described herein, comprises an antibody heavy chain constant region and an antibody light chain constant region. In some embodiments, the anti-TSLP antibody comprises an IgG1-type heavy chain constant region. In some embodiments, the anti-TSLP antibody comprises an IgG2-type heavy chain constant region. In some embodiments, the anti-TSLP antibody comprises an IgG3-type heavy chain constant region. In some embodiments, the anti-TSLP antibody comprises an IgG4-type heavy chain constant region. In some embodiments, the heavy chain constant region comprises (including consisting of, or consisting essentially of) the amino acid sequence SEQ ID NO:124. In some embodiments, the heavy chain constant region comprises (including consisting of, or consisting essentially of) the amino acid sequence SEQ ID NO:125. In some embodiments, the anti-TSLP antibody comprises a λ light chain constant region. In some embodiments, the anti-TSLP antibody comprises a κ light chain constant region. In some embodiments, the light chain constant region comprises (including consisting of, or consisting essentially of) the amino acid sequence SEQ ID NO:126. In some embodiments, the anti-TSLP antibody comprises a lambda light chain constant region. In some embodiments, the light chain constant region comprises (including consisting of, or consisting essentially of) the amino acid sequence of SEQ ID NO:127. In some embodiments, the anti-TSLP antibody comprises an antibody heavy chain variable domain and an antibody light chain variable domain.

[0084] In some embodiments, the anti-TSLP antibody comprises an HC-CDR1 comprising SGYGWS (SEQ ID NO: 1), an HC-CDR2 comprising YX1SYYGSX2SYNPSLKS (SEQ ID NO: 103), where X1 is I or F and X2 is I or T, and an HC-CDR3 comprising TNLLYFX1X2 (SEQ ID NO: 104), where X1 is D or E and X2 is S or Y. Hand a light chain complementarity determining region (LC-CDR) 1 comprising RASQX1X2SX3X4LA (SEQ ID NO: 105) (wherein X1 is G or S, X2 is V or I, X3 is N or S, and X4 is N or Y), a LC-CDR2 comprising DX1SX2X3X4X5 (SEQ ID NO: 106) (wherein X1 is A or T, X2 is S or N, X2 is S or N, X4 is A or Q, and X5 is T or S), and a V comprising LC-CDR3 comprising QQYSX1WPX2YX3 (SEQ ID NO: 107) (wherein X1 is D or N, X2 is Q or E, and X3 is T or S). L and,

[0085] In some embodiments, the anti-TSLP antibody is V H and V H include an HC-CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 1 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions; an HC-CDR3 comprising the amino acid sequence set forth in any of SEQ ID NOs: 7 to 9 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions; and an HC-CDR3 comprising the amino acid sequence set forth in any of SEQ ID NOs: 16 to 18 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions.

[0086] In some embodiments, the anti-TSLP antibody is V H and V H comprises an HC-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence shown in any of SEQ ID NOs: 7 to 9, and an HC-CDR3 comprising the amino acid sequence shown in any of SEQ ID NOs: 16 to 18.

[0087] In some embodiments, the anti-TSLP antibody is V L and V LThe LC-CDR1 includes an LC-CDR1 having an amino acid sequence set forth in any of SEQ ID NOs: 25 to 28 or a variant thereof having up to about three (e.g., one, two, or three) amino acid substitutions; an LC-CDR2 having an amino acid sequence set forth in any of SEQ ID NOs: 39 to 41 or a variant thereof having up to about three (e.g., one, two, or three) amino acid substitutions; and an LC-CDR3 having an amino acid sequence set forth in any of SEQ ID NOs: 50 to 53 or a variant thereof having up to about three (e.g., one, two, or three) amino acid substitutions.

[0088] In some embodiments, the anti-TSLP antibody is V L and V L comprises an LC-CDR1 comprising the amino acid sequence shown in any one of SEQ ID NOs: 25 to 28, an LC-CDR2 comprising the amino acid sequence shown in any one of SEQ ID NOs: 39 to 41, and an LC-CDR3 comprising the amino acid sequence shown in any one of SEQ ID NOs: 50 to 53.

[0089] In some embodiments, the anti-TSLP antibody comprises an HC-CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 1 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions; an HC-CDR3 comprising the amino acid sequence set forth in any of SEQ ID NOs: 7-9 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions; and a V comprising an HC-CDR3 comprising the amino acid sequence set forth in any of SEQ ID NOs: 16-18 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions. Hand V comprising an LC-CDR1 comprising an amino acid sequence set forth in any of SEQ ID NOs: 25 to 28 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions; an LC-CDR2 comprising an amino acid sequence set forth in any of SEQ ID NOs: 39 to 41 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions; and an LC-CDR3 comprising an amino acid sequence set forth in any of SEQ ID NOs: 50 to 53 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions. L and,

[0090] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 1, a HC-CDR2 comprising the amino acid sequence set forth in any of SEQ ID NOs: 7 to 9, and a HC-CDR3 comprising the amino acid sequence set forth in any of SEQ ID NOs: 16 to 18. H and a V comprising an LC-CDR1 having an amino acid sequence represented by any one of SEQ ID NOs: 25 to 28, an LC-CDR2 having an amino acid sequence represented by any one of SEQ ID NOs: 39 to 41, and an LC-CDR3 having an amino acid sequence represented by any one of SEQ ID NOs: 50 to 53. L and,

[0091] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:1, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:7, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:16. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:25, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:39, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:50. L or the V containing up to about five amino acid substitutions in its LC-CDRs.L and variants of

[0092] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:1, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:7, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:16. H and V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO: 25, an LC-CDR2 comprising the amino acid sequence SEQ ID NO: 39, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO: 50. L and,

[0093] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:1, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:8, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:16. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V variant comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:25, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:39, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:51. L or the V containing up to about five amino acid substitutions in its LC-CDRs. L and variants of

[0094] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:1, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:8, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:16. H and V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO: 25, an LC-CDR2 comprising the amino acid sequence SEQ ID NO: 39, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO: 51. L and,

[0095] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:1, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:8, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:17. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V variant comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:26, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:40, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:52. L or the V containing up to about five amino acid substitutions in its LC-CDRs. L and variants of

[0096] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:1, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:8, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:17. H and V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO: 26, an LC-CDR2 comprising the amino acid sequence SEQ ID NO: 40, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO: 52. L and,

[0097] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:1, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:8, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:16. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:27, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:41, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:52. L or the V containing up to about five amino acid substitutions in its LC-CDRs.L and variants of

[0098] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:1, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:8, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:16. H and V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO: 27, an LC-CDR2 comprising the amino acid sequence SEQ ID NO: 41, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO: 52. L and,

[0099] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:1, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:9, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:16. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:28, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:39, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:52. L or the V containing up to about five amino acid substitutions in its LC-CDRs. L and variants of

[0100] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:1, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:9, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:16. H and V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO: 28, an LC-CDR2 comprising the amino acid sequence SEQ ID NO: 39, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO: 52. L and,

[0101] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:1, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:8, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:18. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:27, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:39, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:53. L or the V containing up to about five amino acid substitutions in its LC-CDRs. L and variants of

[0102] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:1, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:8, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:18. H and V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO: 27, an LC-CDR2 comprising the amino acid sequence SEQ ID NO: 39, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO: 53. L and,

[0103] In some embodiments, the anti-TSLP antibody comprises a V antibody comprising an amino acid sequence set forth in SEQ ID NOs: 1, 7-9, 16-18. H , or V containing up to about five amino acid substitutions H and variants of V having the amino acid sequences shown in SEQ ID NOs: 25-28, 39-41, and 50-53. L , or V containing up to about five amino acid substitutions L In some embodiments, the anti-TSLP antibody comprises a V variant comprising an amino acid sequence set forth in SEQ ID NOs: 1, 7-9, 16-18. Hand V comprising the amino acid sequences shown in SEQ ID NOs: 25-28, 39-41, and 50-53. L and,

[0104] In some embodiments, the anti-TSLP antibody comprises a V antibody comprising the amino acid sequence SEQ ID NOs: 1, 7, and 16. H , or V containing up to five amino acid substitutions H and variants of V including amino acid sequences SEQ ID NOs: 25, 39 and 50. L , or V containing up to five amino acid substitutions L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NOs: 1, 7, and 16. H and V comprising the amino acid sequences SEQ ID NOs: 25, 39 and 50. L and,

[0105] In some embodiments, the anti-TSLP antibody comprises a V antibody comprising the amino acid sequence SEQ ID NOs: 1, 8, and 16. H , or V containing up to five amino acid substitutions H and variants of V including amino acid sequences SEQ ID NOs: 25, 39 and 51. L , or V containing up to five amino acid substitutions L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NOs: 1, 8, and 16. H and V comprising the amino acid sequences SEQ ID NOs: 25, 39 and 51. L and,

[0106] In some embodiments, the anti-TSLP antibody comprises a V antibody comprising the amino acid sequence SEQ ID NOs: 1, 8, and 17. H , or V containing up to five amino acid substitutions H and variants of V including amino acid sequences SEQ ID NOs: 26, 40 and 52. L , or V containing up to five amino acid substitutions LIn some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NOs: 1, 8, and 17. H and V comprising the amino acid sequences SEQ ID NOs: 26, 40 and 52. L and,

[0107] In some embodiments, the anti-TSLP antibody comprises a V antibody comprising the amino acid sequence SEQ ID NOs: 1, 8, and 16. H , or V containing up to five amino acid substitutions H and variants of V including amino acid sequences SEQ ID NOs: 27, 41 and 52. L , or V containing up to five amino acid substitutions L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NOs: 1, 8, and 16. H and V comprising the amino acid sequences SEQ ID NOs: 27, 41 and 52. L and,

[0108] In some embodiments, the anti-TSLP antibody comprises a V antibody comprising the amino acid sequence SEQ ID NOs: 1, 9, and 16. H , or V containing up to five amino acid substitutions H and variants of V including amino acid sequences SEQ ID NOs: 28, 39 and 52. L , or V containing up to five amino acid substitutions L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NOs: 1, 9, and 16. H and V comprising the amino acid sequences SEQ ID NOs: 28, 39 and 52. L and,

[0109] In some embodiments, the anti-TSLP antibody comprises a V antibody comprising the amino acid sequence SEQ ID NOs: 1, 8, and 18. H , or V containing up to five amino acid substitutions H and variants of V including amino acid sequences SEQ ID NOs: 27, 39 and 53.L , or V containing up to five amino acid substitutions L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NOs: 1, 8, and 18. H and V comprising the amino acid sequences SEQ ID NOs: 27, 39 and 53. L and,

[0110] In some embodiments, the anti-TSLP antibody is a V antibody having an amino acid sequence represented by any one of SEQ ID NOs: 65 to 72. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V represented by any one of the amino acid sequences of SEQ ID NOs: 84 to 90. L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and,

[0111] In some embodiments, the anti-TSLP antibody is V H and V H is V as shown in the amino acid sequence SEQ ID NO:65 H In some embodiments, the anti-TSLP antibody comprises one, two, or three HC-CDRs comprised in V H and V H is V as shown in the amino acid sequence SEQ ID NO:66 H In some embodiments, the anti-TSLP antibody comprises one, two, or three HC-CDRs comprised in V H and V H is V as shown in the amino acid sequence SEQ ID NO:67 H In some embodiments, the anti-TSLP antibody comprises one, two, or three HC-CDRs comprised in V H and V H is V as shown in the amino acid sequence SEQ ID NO:68 H In some embodiments, the anti-TSLP antibody comprises one, two, or three HC-CDRs comprised in V Hand V H is V as shown in the amino acid sequence SEQ ID NO:69 H In some embodiments, the anti-TSLP antibody comprises one, two, or three HC-CDRs comprised in V H and V H is V as shown in the amino acid sequence SEQ ID NO:70 H In some embodiments, the anti-TSLP antibody comprises one, two, or three HC-CDRs comprised in V H and V H is V as shown in the amino acid sequence SEQ ID NO:71 H In some embodiments, the anti-TSLP antibody comprises one, two, or three HC-CDRs comprised in V H and V H is V as shown in the amino acid sequence SEQ ID NO:72 H and 1, 2, or 3 HC-CDRs contained in

[0112] In some embodiments, the anti-TSLP antibody is V L and V L is V as shown in the amino acid sequence SEQ ID NO:84 L In some embodiments, the anti-TSLP antibody comprises one, two, or three LC-CDRs comprised in V L and V L is V as shown in the amino acid sequence SEQ ID NO:85 L In some embodiments, the anti-TSLP antibody comprises one, two, or three LC-CDRs comprised in V L and V L is V as shown in the amino acid sequence SEQ ID NO:86 L In some embodiments, the anti-TSLP antibody comprises one, two, or three LC-CDRs comprised in V L and V L is V as shown in the amino acid sequence SEQ ID NO:87 LIn some embodiments, the anti-TSLP antibody comprises one, two, or three LC-CDRs comprised in V L and V L is V as shown in the amino acid sequence SEQ ID NO:88 L In some embodiments, the anti-TSLP antibody comprises one, two, or three LC-CDRs comprised in V L and V L is V as shown in the amino acid sequence SEQ ID NO:89 L In some embodiments, the anti-TSLP antibody comprises one, two, or three LC-CDRs comprised in V L and V L is V as shown in the amino acid sequence SEQ ID NO:90 L and containing one, two or three LC-CDRs contained in

[0113] In some embodiments, the anti-TSLP antibody has the amino acid sequence V as set forth in SEQ ID NO:65. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:84. L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L In some embodiments, the anti-TSLP antibody comprises the V sequence set forth in the amino acid sequence SEQ ID NO:65. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:85 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L In some embodiments, the anti-TSLP antibody comprises the V sequence set forth in the amino acid sequence SEQ ID NO:66. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:84. LV containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L In some embodiments, the anti-TSLP antibody comprises the V sequence set forth in the amino acid sequence SEQ ID NO:66. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:85 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L In some embodiments, the anti-TSLP antibody comprises the V sequence set forth in the amino acid sequence SEQ ID NO:67. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:84. L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L In some embodiments, the anti-TSLP antibody comprises the V sequence set forth in the amino acid sequence SEQ ID NO:67. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:85 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L In some embodiments, the anti-TSLP antibody comprises the V sequence set forth in the amino acid sequence SEQ ID NO:68. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:84. L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L In some embodiments, the anti-TSLP antibody comprises the V sequence set forth in the amino acid sequence SEQ ID NO:68. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:85 LV containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L In some embodiments, the anti-TSLP antibody comprises the V sequence set forth in the amino acid sequence SEQ ID NO:69. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:86 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L In some embodiments, the anti-TSLP antibody comprises the V sequence set forth in the amino acid sequence SEQ ID NO:70. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:87 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L In some embodiments, the anti-TSLP antibody comprises the V sequence set forth in the amino acid sequence SEQ ID NO:69. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:88 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L In some embodiments, the anti-TSLP antibody comprises the V sequence set forth in the amino acid sequence SEQ ID NO:71. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:89 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L In some embodiments, the anti-TSLP antibody comprises the amino acid sequence V shown in SEQ ID NO:72. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:90 LV containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and,

[0114] In some embodiments, the anti-TSLP antibody comprises a V antibody comprising an amino acid sequence set forth in any of SEQ ID NOs: 65 to 72. H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to any of the amino acid sequences of SEQ ID NOs: 65 to 72. H and a V having an amino acid sequence represented by any one of SEQ ID NOs: 84 to 90. L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to any of the amino acid sequences of SEQ ID NOs: 84 to 90. L In some embodiments, the anti-TSLP antibody comprises a V variant comprising an amino acid sequence set forth in any of SEQ ID NOs: 65-72. H and V comprising an amino acid sequence represented by any one of SEQ ID NOs: 84 to 90. L and,

[0115] In some embodiments, the anti-TSLP antibody comprises a V comprising the amino acid sequence SEQ ID NO:65. H or a variant thereof having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO:65. H and a variant of V comprising the amino acid sequence SEQ ID NO:84. L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 84. LIn some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NO:65. H and V comprising the amino acid sequence SEQ ID NO:84 L and,

[0116] In some embodiments, the anti-TSLP antibody comprises a V comprising the amino acid sequence SEQ ID NO:65. H or a variant thereof having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO:65. H and a variant of V comprising the amino acid sequence SEQ ID NO:85. L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 85. L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NO:65. H and V comprising the amino acid sequence SEQ ID NO:85 L and,

[0117] In some embodiments, the anti-TSLP antibody comprises a V polypeptide comprising the amino acid sequence SEQ ID NO:66. H or a variant thereof having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO:66. H and a variant of V comprising the amino acid sequence SEQ ID NO:84. H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO:84. H In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NO:66.H and V comprising the amino acid sequence SEQ ID NO:84 L and,

[0118] In some embodiments, the anti-TSLP antibody comprises a V polypeptide comprising the amino acid sequence SEQ ID NO:66. H or a variant thereof having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO:66. H and a variant of V comprising the amino acid sequence SEQ ID NO:85. L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 85. L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NO:66. H and V comprising the amino acid sequence SEQ ID NO:85 L and,

[0119] In some embodiments, the anti-TSLP antibody comprises a V comprising the amino acid sequence SEQ ID NO:67. H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO:67. H and a variant of V comprising the amino acid sequence SEQ ID NO:84. L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 84. L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NO:67. H and V comprising the amino acid sequence SEQ ID NO:84 L and,

[0120] In some embodiments, the anti-TSLP antibody comprises a V comprising the amino acid sequence SEQ ID NO:67. H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO:67. H and a variant of V comprising the amino acid sequence SEQ ID NO:85. L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 85. L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NO:67. H and V comprising the amino acid sequence SEQ ID NO:85 L and,

[0121] In some embodiments, the anti-TSLP antibody comprises a V polypeptide comprising the amino acid sequence SEQ ID NO:68. H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 68. H and a variant of V comprising the amino acid sequence SEQ ID NO:84. L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 84. L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NO:68. H and V comprising the amino acid sequence SEQ ID NO:84 L and,

[0122] In some embodiments, the anti-TSLP antibody comprises a V polypeptide comprising the amino acid sequence SEQ ID NO:68.H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 68. H and a variant of V comprising the amino acid sequence SEQ ID NO:85. L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 85. L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NO:68. H and V comprising the amino acid sequence SEQ ID NO:85 L and,

[0123] In some embodiments, the anti-TSLP antibody comprises a V comprising the amino acid sequence SEQ ID NO:69. H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO:69. H and a variant of V comprising the amino acid sequence SEQ ID NO:86. L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 86. L and a variant of V comprising the amino acid sequence SEQ ID NO:69. In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NO:69. H and V comprising the amino acid sequence SEQ ID NO:86 L and,

[0124] In some embodiments, the anti-TSLP antibody comprises a V comprising the amino acid sequence SEQ ID NO:70. Hor a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 70. H and a variant of V comprising the amino acid sequence SEQ ID NO:87. L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 87. L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NO:70. H and V comprising the amino acid sequence SEQ ID NO:87 L and,

[0125] In some embodiments, the anti-TSLP antibody comprises a V comprising the amino acid sequence SEQ ID NO:69. H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO:69. H and a variant of V comprising the amino acid sequence SEQ ID NO:88. L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 88. L and a variant of V comprising the amino acid sequence SEQ ID NO:69. In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NO:69. H and V comprising the amino acid sequence SEQ ID NO:88 L and,

[0126] In some embodiments, the anti-TSLP antibody comprises a V polypeptide comprising the amino acid sequence SEQ ID NO:71. Hor a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 71. H and a variant of V comprising the amino acid sequence SEQ ID NO:89. L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 89. L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NO:71. H and V comprising the amino acid sequence SEQ ID NO:89 L and,

[0127] In some embodiments, the anti-TSLP antibody comprises a V comprising the amino acid sequence SEQ ID NO:72. H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 72. H and a variant of V comprising the amino acid sequence SEQ ID NO:90 L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 90. L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NO:72. H and V comprising the amino acid sequence SEQ ID NO:90 L and,

[0128] In some embodiments, the anti-TSLP antibody comprises an HC-CDR1 comprising SYGIX1 (SEQ ID NO: 108) (wherein X1 is N or S), an HC-CDR2 comprising VIX1PLX2X3VX4X5YAEKFQG (SEQ ID NO: 109) (wherein X1 is V or I, X2 is V or L, X3 is G or D, X4 is T or P, and X5 is I or N), and an HC-CDR3 comprising GX1EYFYWYFDL (SEQ ID NO: 110) (wherein X1 is Q or A). H and a light chain complementarity determining region (LC-CDR) 1 comprising X1GX2X3SDIGGYX4RVS (SEQ ID NO: 111) (wherein X1 is S or T, X2 is S or T, X3 is S, T, I or N, and X4 is N or D); a LC-CDR2 comprising X1X2X3KRX4S (SEQ ID NO: 112) (wherein X1 is D, G or E, X2 is V, F or I, X3 is S or N, and X4 is P or S); and a light chain complementarity determining region (LC-CDR) 2 comprising X1SYAX2X3X4X5FX6X7 (SEQ ID NO: 113) (wherein X1 is D, G or E, X2 is V, F or I, X3 is S or N, and X4 is P or S). and a light chain variable domain (V) comprising an LC-CDR3 (wherein X1 is S or T, X2 is G or S, X3 is T or G, X4 is D or H, X5 is T or I, X6 is I, G, V, or A, and X7 is L, I, or F) comprising a light chain variable domain (V). L ) and,

[0129] In some embodiments, the anti-TSLP antibody is V H and V HThe HC-CDR1 includes an HC-CDR1 having an amino acid sequence set forth in any of SEQ ID NOs: 2 to 3 or a variant thereof having up to about three (e.g., one, two, or three) amino acid substitutions; an HC-CDR2 includes an amino acid sequence set forth in any of SEQ ID NOs: 10 to 12 or a variant thereof having up to about three (e.g., one, two, or three) amino acid substitutions; and an HC-CDR3 includes an amino acid sequence set forth in any of SEQ ID NOs: 19 to 20 or a variant thereof having up to about three (e.g., one, two, or three) amino acid substitutions.

[0130] In some embodiments, the anti-TSLP antibody is V H and V H comprises an HC-CDR1 comprising the amino acid sequence shown in any one of SEQ ID NOs: 2 to 3, an HC-CDR2 comprising the amino acid sequence shown in any one of SEQ ID NOs: 10 to 12, and an HC-CDR3 comprising the amino acid sequence shown in any one of SEQ ID NOs: 19 to 20.

[0131] In some embodiments, the anti-TSLP antibody is V L and V L The LC-CDR1 includes an LC-CDR1 having an amino acid sequence set forth in any of SEQ ID NOs: 29 to 34 or a variant thereof having up to about three (e.g., one, two, or three) amino acid substitutions; an LC-CDR2 having an amino acid sequence set forth in any of SEQ ID NOs: 42 to 47 or a variant thereof having up to about three (e.g., one, two, or three) amino acid substitutions; and an LC-CDR3 having an amino acid sequence set forth in any of SEQ ID NOs: 54 to 60 or a variant thereof having up to about three (e.g., one, two, or three) amino acid substitutions.

[0132] In some embodiments, the anti-TSLP antibody is V L and V Lcomprises an LC-CDR1 comprising the amino acid sequence shown in any one of SEQ ID NOs: 29 to 34, an LC-CDR2 comprising the amino acid sequence shown in any one of SEQ ID NOs: 42 to 47, and an LC-CDR3 comprising the amino acid sequence shown in any one of SEQ ID NOs: 54 to 60.

[0133] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising an HC-CDR1 having an amino acid sequence set forth in any of SEQ ID NOs: 2-3 or a variant thereof containing up to about three (e.g., one, two, or three) amino acid substitutions; a V-CDR2 comprising an amino acid sequence set forth in any of SEQ ID NOs: 10-12 or a variant thereof containing up to about three (e.g., one, two, or three) amino acid substitutions; and a V-CDR3 comprising an amino acid sequence set forth in any of SEQ ID NOs: 19-20 or a variant thereof containing up to about three (e.g., one, two, or three) amino acid substitutions. H and V comprising an LC-CDR1 comprising an amino acid sequence set forth in any of SEQ ID NOs: 29 to 34 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions; an LC-CDR2 comprising an amino acid sequence set forth in any of SEQ ID NOs: 42 to 47 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions; and an LC-CDR3 comprising an amino acid sequence set forth in any of SEQ ID NOs: 54 to 60 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions. L and,

[0134] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising an HC-CDR1 having an amino acid sequence set forth in any one of SEQ ID NOs: 2 to 3, an HC-CDR2 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 10 to 12, and an HC-CDR3 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 19 to 20. Hand a V comprising an LC-CDR1 having an amino acid sequence represented by any one of SEQ ID NOs: 29 to 34, an LC-CDR2 having an amino acid sequence represented by any one of SEQ ID NOs: 42 to 47, and an LC-CDR3 having an amino acid sequence represented by any one of SEQ ID NOs: 54 to 60. L and,

[0135] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:2, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:10, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:19. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:29, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:42, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:54. L or the V containing up to about five amino acid substitutions in its LC-CDRs. L and variants of

[0136] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:2, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:10, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:19. H and V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO: 29, an LC-CDR2 comprising the amino acid sequence SEQ ID NO: 42, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO: 54. L and,

[0137] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:2, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:10, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:19. Hor the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO: 30, an LC-CDR2 comprising the amino acid sequence SEQ ID NO: 43, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO: 55. L or the V containing up to about five amino acid substitutions in its LC-CDRs. L and variants of

[0138] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:2, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:10, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:19. H and V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO: 30, an LC-CDR2 comprising the amino acid sequence SEQ ID NO: 43, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO: 55. L and,

[0139] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:2, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:10, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:19. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V variant comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:31, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:44, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:56. L or the V containing up to about five amino acid substitutions in its LC-CDRs. L and variants of

[0140] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:2, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:10, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:19. H and V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO: 31, an LC-CDR2 comprising the amino acid sequence SEQ ID NO: 44, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO: 56. L and,

[0141] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:2, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:10, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:19. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO: 32, an LC-CDR2 comprising the amino acid sequence SEQ ID NO: 45, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO: 57. L or the V containing up to about five amino acid substitutions in its LC-CDRs. L and variants of

[0142] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:2, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:10, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:19. H and V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO: 32, an LC-CDR2 comprising the amino acid sequence SEQ ID NO: 45, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO: 57. L and,

[0143] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:3, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:11, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:19. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO: 33, an LC-CDR2 comprising the amino acid sequence SEQ ID NO: 45, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO: 58. L or the V containing up to about five amino acid substitutions in its LC-CDRs. L and variants of

[0144] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:3, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:11, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:19. H and V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO: 33, an LC-CDR2 comprising the amino acid sequence SEQ ID NO: 45, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO: 58. L and,

[0145] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:3, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:10, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:19. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:31, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:46, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:59. L or the V containing up to about five amino acid substitutions in its LC-CDRs.L and variants of

[0146] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:3, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:10, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:19. H and V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO: 31, an LC-CDR2 comprising the amino acid sequence SEQ ID NO: 46, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO: 59. L and,

[0147] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:3, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:12, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:20. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:34, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:47, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:60. L or the V containing up to about five amino acid substitutions in its LC-CDRs. L and variants of

[0148] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:3, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:12, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:20. H and V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO: 34, an LC-CDR2 comprising the amino acid sequence SEQ ID NO: 47, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO: 60. L and,

[0149] In some embodiments, the anti-TSLP antibody comprises a V antibody comprising the amino acid sequence set forth in SEQ ID NOs: 2-3, 10-12, 19-20. H , or V containing up to about five amino acid substitutions H and variants of V having the amino acid sequences shown in SEQ ID NOs: 29-34, 42-47, and 54-60. L , or V containing up to about five amino acid substitutions L In some embodiments, the anti-TSLP antibody comprises a V variant comprising an amino acid sequence set forth in SEQ ID NOs: 2-3, 10-12, 19-20. H and V comprising the amino acid sequences shown in SEQ ID NOs: 29-34, 42-47, and 54-60. L and,

[0150] In some embodiments, the anti-TSLP antibody comprises a V antibody comprising the amino acid sequence SEQ ID NOs: 2, 10, and 19. H , or V containing up to five amino acid substitutions H and variants of V including amino acid sequences SEQ ID NOs: 29, 42 and 54 L , or V containing up to five amino acid substitutions L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NOs: 2, 10, and 19. H and V comprising the amino acid sequences SEQ ID NOs: 29, 42 and 54. L and,

[0151] In some embodiments, the anti-TSLP antibody comprises a V antibody comprising the amino acid sequence SEQ ID NOs: 2, 10, and 19. H , or V containing up to five amino acid substitutions H and variants of V including amino acid sequences SEQ ID NOs: 30, 43 and 55. L , or V containing up to five amino acid substitutions LIn some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NOs: 2, 10, and 19. H and V comprising the amino acid sequences SEQ ID NOs: 30, 43 and 55. L and,

[0152] In some embodiments, the anti-TSLP antibody comprises a V antibody comprising the amino acid sequence SEQ ID NOs: 2, 10, and 19. H , or V containing up to five amino acid substitutions H and variants of V including amino acid sequences SEQ ID NOs: 31, 44 and 56. L , or V containing up to five amino acid substitutions L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NOs: 2, 10, and 19. H and V comprising the amino acid sequences SEQ ID NOs: 31, 44 and 56. L and,

[0153] In some embodiments, the anti-TSLP antibody comprises a V antibody comprising the amino acid sequence SEQ ID NOs: 2, 10, and 19. H , or V containing up to five amino acid substitutions H and variants of V including amino acid sequences SEQ ID NOs: 32, 45 and 57. L , or V containing up to five amino acid substitutions L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NOs: 2, 10, and 19. H and V comprising the amino acid sequences SEQ ID NOs: 32, 45 and 57. L and,

[0154] In some embodiments, the anti-TSLP antibody comprises a V antibody comprising the amino acid sequence SEQ ID NOs: 3, 11, and 19. H , or V containing up to five amino acid substitutions Hand variants of V including amino acid sequences SEQ ID NOs: 33, 45 and 58. L , or V containing up to five amino acid substitutions L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NOs: 3, 11, and 19. H and V comprising the amino acid sequences SEQ ID NOs: 33, 45 and 58. L and,

[0155] In some embodiments, the anti-TSLP antibody comprises a V antibody comprising the amino acid sequence SEQ ID NOs: 3, 10, and 19. H , or V containing up to five amino acid substitutions H and variants of V including amino acid sequences SEQ ID NOs: 31, 46 and 59. L , or V containing up to five amino acid substitutions L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NOs: 3, 10, and 19. H and V comprising the amino acid sequences SEQ ID NOs: 31, 46 and 59. L and,

[0156] In some embodiments, the anti-TSLP antibody comprises a V antibody comprising the amino acid sequence SEQ ID NOs: 3, 12, and 20. H , or V containing up to five amino acid substitutions H and variants of V including amino acid sequences SEQ ID NOs: 34, 47 and 60. L , or V containing up to five amino acid substitutions L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NOs: 3, 12, and 20. H and V comprising the amino acid sequences SEQ ID NOs: 34, 47 and 60. L and,

[0157] In some embodiments, the anti-TSLP antibody is a V antibody having an amino acid sequence represented by any one of SEQ ID NOs:73 to 78. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V represented by any one of the amino acid sequences of SEQ ID NOs: 91 to 97. L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and,

[0158] In some embodiments, the anti-TSLP antibody is V H and V H is V as shown in the amino acid sequence SEQ ID NO:73 H In some embodiments, the anti-TSLP antibody comprises one, two, or three HC-CDRs comprised in V H and V H is V as shown in the amino acid sequence SEQ ID NO:74 H In some embodiments, the anti-TSLP antibody comprises one, two, or three HC-CDRs comprised in V H and V H is V as shown in the amino acid sequence SEQ ID NO:75 H In some embodiments, the anti-TSLP antibody comprises one, two, or three HC-CDRs comprised in V H and V H is V as shown in the amino acid sequence SEQ ID NO:76 H In some embodiments, the anti-TSLP antibody comprises one, two, or three HC-CDRs comprised in V H and V H is V as shown in the amino acid sequence SEQ ID NO:77 H In some embodiments, the anti-TSLP antibody comprises one, two, or three HC-CDRs comprised in V H and V H is V as shown in the amino acid sequence SEQ ID NO:78 H and 1, 2, or 3 HC-CDRs contained in

[0159] In some embodiments, the anti-TSLP antibody is V L and V L is V as shown in the amino acid sequence SEQ ID NO:91 L In some embodiments, the anti-TSLP antibody V comprises one, two, or three LC-CDRs comprised in L and V L is V as shown in the amino acid sequence SEQ ID NO:92 L In some embodiments, the anti-TSLP antibody comprises one, two, or three LC-CDRs comprised in V L and V L is V as shown in the amino acid sequence SEQ ID NO:93 L In some embodiments, the anti-TSLP antibody comprises one, two, or three LC-CDRs comprised in V L and V L is V as shown in the amino acid sequence SEQ ID NO:94 L In some embodiments, the anti-TSLP antibody comprises one, two, or three LC-CDRs comprised in V L and V L is V as shown in the amino acid sequence SEQ ID NO:95 L In some embodiments, the anti-TSLP antibody comprises one, two, or three LC-CDRs comprised in V L and V L is V as shown in the amino acid sequence SEQ ID NO:96 L In some embodiments, the anti-TSLP antibody comprises one, two, or three LC-CDRs comprised in V L and V L is V as shown in the amino acid sequence SEQ ID NO:97 L and containing one, two or three LC-CDRs contained in

[0160] In some embodiments, the anti-TSLP antibody has the amino acid sequence V as set forth in SEQ ID NO:73. HV containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:9 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L In some embodiments, the anti-TSLP antibody comprises the V sequence set forth in the amino acid sequence SEQ ID NO:74. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:91. L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L In some embodiments, the anti-TSLP antibody comprises the V sequence set forth in the amino acid sequence SEQ ID NO:75. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:91. L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L In some embodiments, the anti-TSLP antibody comprises the V sequence set forth in the amino acid sequence SEQ ID NO:73. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:92 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L In some embodiments, the anti-TSLP antibody comprises the V sequence set forth in the amino acid sequence SEQ ID NO:73. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:93 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L In some embodiments, the anti-TSLP antibody comprises the V sequence set forth in the amino acid sequence SEQ ID NO:73. HV containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:94 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L In some embodiments, the anti-TSLP antibody comprises the V sequence set forth in the amino acid sequence SEQ ID NO:76. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:95 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L In some embodiments, the anti-TSLP antibody comprises the V sequence set forth in the amino acid sequence SEQ ID NO:77. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:96 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L In some embodiments, the anti-TSLP antibody comprises the V sequence set forth in the amino acid sequence SEQ ID NO:78. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:97 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and,

[0161] In some embodiments, the anti-TSLP antibody comprises a V antibody comprising an amino acid sequence set forth in any of SEQ ID NOs: 73-78. H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to any of the amino acid sequences of SEQ ID NOs: 73 to 78. Hand a V having an amino acid sequence represented by any of SEQ ID NOs: 91 to 97. L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 91-97. L In some embodiments, the anti-TSLP antibody comprises a V variant comprising an amino acid sequence set forth in any of SEQ ID NOs: 73-78. H and V comprising an amino acid sequence represented by any one of SEQ ID NOs: 91 to 97. L and,

[0162] In some embodiments, the anti-TSLP antibody comprises a V polypeptide comprising the amino acid sequence SEQ ID NO:73. H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 73. H and a variant of V comprising the amino acid sequence SEQ ID NO:91. L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 91. L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NO:73. H and V comprising the amino acid sequence SEQ ID NO:91 L and,

[0163] In some embodiments, the anti-TSLP antibody comprises a V comprising the amino acid sequence SEQ ID NO:74. H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO:74. H and a variant of V comprising the amino acid sequence SEQ ID NO:91.L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 91. L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NO:74. H and V comprising the amino acid sequence SEQ ID NO:91 L and,

[0164] In some embodiments, the anti-TSLP antibody comprises a V polypeptide comprising the amino acid sequence SEQ ID NO:75. H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 75. H and a variant of V comprising the amino acid sequence SEQ ID NO:91. L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 91. L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NO:75. H and V comprising the amino acid sequence SEQ ID NO:91 L and,

[0165] In some embodiments, the anti-TSLP antibody comprises a V polypeptide comprising the amino acid sequence SEQ ID NO:73. H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 73. H and a variant of V comprising the amino acid sequence SEQ ID NO:92. Lor a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 92. L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NO:73. H and V comprising the amino acid sequence SEQ ID NO:92 L and,

[0166] In some embodiments, the anti-TSLP antibody comprises a V polypeptide comprising the amino acid sequence SEQ ID NO:73. H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 73. H and a variant of V comprising the amino acid sequence SEQ ID NO:93 L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 93. L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NO:73. H and V comprising the amino acid sequence SEQ ID NO:93 L and,

[0167] In some embodiments, the anti-TSLP antibody comprises a V polypeptide comprising the amino acid sequence SEQ ID NO:73. H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 73. H and a variant of V comprising the amino acid sequence SEQ ID NO:94. Lor a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO:94. L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NO:73. H and V comprising the amino acid sequence SEQ ID NO:94 L and,

[0168] In some embodiments, the anti-TSLP antibody comprises a V polypeptide comprising the amino acid sequence SEQ ID NO:76. H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 76. H and a variant of V comprising the amino acid sequence SEQ ID NO:95. L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 95. L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NO:76. H and V comprising the amino acid sequence SEQ ID NO:95 L and,

[0169] In some embodiments, the anti-TSLP antibody comprises a V comprising the amino acid sequence SEQ ID NO:77. H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 77. H and a variant of V comprising the amino acid sequence SEQ ID NO:96. Lor a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 96. L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NO:77. H and V comprising the amino acid sequence SEQ ID NO:96 L and,

[0170] In some embodiments, the anti-TSLP antibody comprises a V polypeptide comprising the amino acid sequence SEQ ID NO:78. H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 78. H and a variant of V comprising the amino acid sequence SEQ ID NO:97 L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 97. L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NO:78. H and V comprising the amino acid sequence SEQ ID NO:97 L and,

[0171] In some embodiments, the anti-TSLP antibody comprises an HC-CDR1 comprising NYX1MT (SEQ ID NO:114), where X1 is D or G; an HC-CDR2 comprising SITFASSYIYYADSVKG (SEQ ID NO:13); and an HC-CDR3 comprising GGGAYX1GGSLDV (SEQ ID NO:115), where X1 is H or Y. Hand a light chain variable domain (V) comprising a light chain complementarity determining region (LC-CDR) 1 comprising RSSQSLLHX1X2X3YTYLH (SEQ ID NO: 116) (wherein X1 is I or S, X2 is N or Y, and X3 is G or E), a LC-CDR2 comprising LVSX1RAS (SEQ ID NO: 117) (wherein X1 is H or Y), and a LC-CDR3 comprising EQTLQTPX1X2 (SEQ ID NO: 118) (wherein X1 is Y or F, and X2 is S or T). L ) and,

[0172] In some embodiments, the anti-TSLP antibody is V H and V H include an HC-CDR1 comprising the amino acid sequence set forth in any of SEQ ID NOs: 4 to 5 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions; an HC-CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 13 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions; and an HC-CDR3 comprising the amino acid sequence set forth in any of SEQ ID NOs: 21 to 22 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions.

[0173] In some embodiments, the anti-TSLP antibody is V H and V H comprises an HC-CDR1 comprising the amino acid sequence shown in SEQ ID NOs: 4 to 5, an HC-CDR2 comprising the amino acid sequence shown in SEQ ID NO: 13, and an HC-CDR3 comprising the amino acid sequence shown in any of SEQ ID NOs: 21 to 22.

[0174] In some embodiments, the anti-TSLP antibody is V L and V LThe LC-CDR1 includes an LC-CDR1 having an amino acid sequence set forth in any of SEQ ID NOs: 35 to 37 or a variant thereof having up to about three (e.g., one, two, or three) amino acid substitutions; an LC-CDR2 having an amino acid sequence set forth in any of SEQ ID NOs: 48 to 49 or a variant thereof having up to about three (e.g., one, two, or three) amino acid substitutions; and an LC-CDR3 having an amino acid sequence set forth in any of SEQ ID NOs: 61 to 63 or a variant thereof having up to about three (e.g., one, two, or three) amino acid substitutions.

[0175] In some embodiments, the anti-TSLP antibody is V L and V L comprises an LC-CDR1 comprising the amino acid sequence shown in any one of SEQ ID NOs: 35 to 37, an LC-CDR2 comprising the amino acid sequence shown in any one of SEQ ID NOs: 48 to 49, and an LC-CDR3 comprising the amino acid sequence shown in any one of SEQ ID NOs: 61 to 63.

[0176] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising an HC-CDR1 having an amino acid sequence set forth in any of SEQ ID NOs: 4-5 or a variant thereof containing up to about three (e.g., one, two, or three) amino acid substitutions; a HC-CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 13 or a variant thereof containing up to about three (e.g., one, two, or three) amino acid substitutions; and a V-CDR3 comprising an amino acid sequence set forth in any of SEQ ID NOs: 21-22 or a variant thereof containing up to about three (e.g., one, two, or three) amino acid substitutions. Hand V comprising an LC-CDR1 comprising an amino acid sequence set forth in any of SEQ ID NOs: 35 to 37 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions; an LC-CDR2 comprising an amino acid sequence set forth in any of SEQ ID NOs: 48 to 49 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions; and an LC-CDR3 comprising an amino acid sequence set forth in any of SEQ ID NOs: 61 to 63 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions. L and,

[0177] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising an HC-CDR1 having an amino acid sequence set forth in any one of SEQ ID NOs: 4 to 5, an HC-CDR2 having an amino acid sequence set forth in SEQ ID NO: 13, and an HC-CDR3 having an amino acid sequence set forth in any one of SEQ ID NOs: 21 to 22. H and a V comprising an LC-CDR1 having an amino acid sequence represented by any one of SEQ ID NOs: 35 to 37, an LC-CDR2 having an amino acid sequence represented by any one of SEQ ID NOs: 48 to 49, and an LC-CDR3 having an amino acid sequence represented by any one of SEQ ID NOs: 61 to 63. L and,

[0178] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:4, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:13, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:21. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO: 35, an LC-CDR2 comprising the amino acid sequence SEQ ID NO: 48, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO: 61. L or the V containing up to about five amino acid substitutions in its LC-CDRs.L and variants of

[0179] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:4, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:13, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:21. H and V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO: 35, an LC-CDR2 comprising the amino acid sequence SEQ ID NO: 48, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO: 61. L and,

[0180] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:4, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:13, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:22. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO: 36, an LC-CDR2 comprising the amino acid sequence SEQ ID NO: 48, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO: 62. L or the V containing up to about five amino acid substitutions in its LC-CDRs. L and variants of

[0181] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:4, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:13, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:22. H and V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO: 36, an LC-CDR2 comprising the amino acid sequence SEQ ID NO: 48, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO: 62. L and,

[0182] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:5, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:13, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:22. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:37, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:49, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:63. L or the V containing up to about five amino acid substitutions in its LC-CDRs. L and variants of

[0183] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:5, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:13, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:22. H and V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO: 37, an LC-CDR2 comprising the amino acid sequence SEQ ID NO: 49, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO: 63. L and,

[0184] In some embodiments, the anti-TSLP antibody comprises a V antibody comprising the amino acid sequence set forth in SEQ ID NOs: 4-5, 13, 21-22. H , or V containing up to about five amino acid substitutions H and variants of V having the amino acid sequences shown in SEQ ID NOs: 35-37, 48-49, and 61-63. L , or V containing up to about five amino acid substitutions L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence set forth in SEQ ID NOs: 4-5, 13, 21-22. Hand V comprising the amino acid sequences shown in SEQ ID NOs: 35-37, 48-49, and 61-63. L and,

[0185] In some embodiments, the anti-TSLP antibody comprises a V antibody comprising the amino acid sequence SEQ ID NOs: 4, 13, and 21. H , or V containing up to five amino acid substitutions H and variants of V including amino acid sequences SEQ ID NOs: 35, 48 and 61. L , or V containing up to five amino acid substitutions L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NOs: 4, 13, and 21. H and V comprising the amino acid sequences SEQ ID NOs: 35, 48 and 61. L and,

[0186] In some embodiments, the anti-TSLP antibody comprises a V antibody comprising the amino acid sequence SEQ ID NOs: 4, 13, and 22. H , or V containing up to five amino acid substitutions H and variants of V including amino acid sequences SEQ ID NOs: 36, 48 and 62. L , or V containing up to five amino acid substitutions L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NOs: 4, 13, and 22. H and V comprising the amino acid sequences SEQ ID NOs: 36, 48 and 62. L Including.

[0187] In some embodiments, the anti-TSLP antibody comprises a V comprising the amino acid sequence SEQ ID NOs: 5, 13, and 22. H , or V containing up to five amino acid substitutions H and variants of V including amino acid sequences SEQ ID NOs: 37, 49 and 63. L , or V containing up to five amino acid substitutions LIn some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NOs: 5, 13, and 22. H and V comprising the amino acid sequences SEQ ID NOs: 37, 49 and 63. L and,

[0188] In some embodiments, the anti-TSLP antibody is a V antibody having an amino acid sequence represented by any one of SEQ ID NOs:79 to 81. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V represented by any one of the amino acid sequences of SEQ ID NOs: 98 to 100. L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and,

[0189] In some embodiments, the anti-TSLP antibody is V H and V H is V as shown in the amino acid sequence SEQ ID NO:79 H In some embodiments, the anti-TSLP antibody comprises one, two, or three HC-CDRs comprised in V H and V H is V as shown in the amino acid sequence SEQ ID NO:80 H In some embodiments, the anti-TSLP antibody comprises one, two, or three HC-CDRs comprised in V H and V H is V as shown in the amino acid sequence SEQ ID NO:81 H and 1, 2, or 3 HC-CDRs contained in

[0190] In some embodiments, the anti-TSLP antibody is V L and V L is V as shown in the amino acid sequence SEQ ID NO:98 L In some embodiments, the anti-TSLP antibody comprises one, two, or three LC-CDRs comprised in V Land V L is V as shown in the amino acid sequence SEQ ID NO:99 L In some embodiments, the anti-TSLP antibody comprises one, two, or three LC-CDRs comprised in V L and V L is V as shown in the amino acid sequence SEQ ID NO:100 L and containing one, two or three LC-CDRs contained in

[0191] In some embodiments, the anti-TSLP antibody has the amino acid sequence V as set forth in SEQ ID NO:79. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:98 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L In some embodiments, the anti-TSLP antibody comprises the V sequence set forth in the amino acid sequence SEQ ID NO:80. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO:99 L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L In some embodiments, the anti-TSLP antibody comprises the V sequence set forth in the amino acid sequence SEQ ID NO:81. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO: 100. L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and,

[0192] In some embodiments, the anti-TSLP antibody comprises an amino acid sequence set forth in any of SEQ ID NOs: 79 to 81. Hor a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to any of the amino acid sequences of SEQ ID NOs: 79 to 81. H and a V having any one of the amino acid sequences of SEQ ID NOs: 98 to 100. L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 98-100. L In some embodiments, the anti-TSLP antibody comprises a V variant comprising an amino acid sequence set forth in any of SEQ ID NOs: 79-81. H and V comprising an amino acid sequence represented by any one of SEQ ID NOs: 98 to 100. L and,

[0193] In some embodiments, the anti-TSLP antibody comprises a V comprising the amino acid sequence SEQ ID NO:79. H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 79. H and a variant of V comprising the amino acid sequence SEQ ID NO:98. L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 98. L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NO:79. H and V comprising the amino acid sequence SEQ ID NO:98 L and,

[0194] In some embodiments, the anti-TSLP antibody comprises a V polypeptide comprising the amino acid sequence SEQ ID NO:80. Hor a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 80. H and a variant of V comprising the amino acid sequence SEQ ID NO:99. L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO:99. L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NO:80. H and V comprising the amino acid sequence SEQ ID NO:99 L and,

[0195] In some embodiments, the anti-TSLP antibody comprises a V polypeptide comprising the amino acid sequence SEQ ID NO:81. H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 81. H and a variant of V comprising the amino acid sequence SEQ ID NO: 100. L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 100. L and a variant of V comprising the amino acid sequence SEQ ID NO:81. H and V comprising the amino acid sequence SEQ ID NO: 100 L and,

[0196] In some embodiments, the anti-TSLP antibody comprises an HC-CDR1 comprising SYAIS (SEQ ID NO:6), an HC-CDR2 comprising MX1X2PLLGVTX3YAEKFQG (SEQ ID NO:119) (wherein X1 is L or I, X2 is V or I, and X3 is N or D), and an HC-CDR3 comprising GGX1NYLYWYFDL (SEQ ID NO:120) (wherein X1 is S or T). H and a light chain complementarity-determining region (LC-CDR) 1 comprising TGTSSDIGGYNRX1S (SEQ ID NO: 121) (wherein X1 is V or I), a light chain CDR2 comprising X1VSKRPS (SEQ ID NO: 122) (wherein X1 is D or E), and a light chain CDR3 comprising SX1YAGTDTFV L (SEQ ID NO: 123), wherein X1 is S or A. L ) and,

[0197] In some embodiments, the anti-TSLP antibody is V H and V H include an HC-CDR1 comprising the amino acid sequence set forth in SEQ ID NO:6 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions; an HC-CDR2 comprising the amino acid sequence set forth in any of SEQ ID NOs:14-15 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions; and an HC-CDR3 comprising the amino acid sequence set forth in any of SEQ ID NOs:23-24 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions.

[0198] In some embodiments, the anti-TSLP antibody is V H and V Hcomprises an HC-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 6, an HC-CDR2 comprising the amino acid sequence shown in any of SEQ ID NOs: 14 to 15, and an HC-CDR3 comprising the amino acid sequence shown in any of SEQ ID NOs: 23 to 24.

[0199] In some embodiments, the anti-TSLP antibody is V L and V L include an LC-CDR1 comprising the amino acid sequence set forth in any of SEQ ID NOs: 31, 38 or a variant thereof comprising up to about three (e.g., one, two or three) amino acid substitutions; an LC-CDR2 comprising the amino acid sequence set forth in any of SEQ ID NOs: 42, 45 or a variant thereof comprising up to about three (e.g., one, two or three) amino acid substitutions; and an LC-CDR3 comprising the amino acid sequence set forth in any of SEQ ID NOs: 60, 64 or a variant thereof comprising up to about three (e.g., one, two or three) amino acid substitutions.

[0200] In some embodiments, the anti-TSLP antibody is V L and V L comprises an LC-CDR1 comprising the amino acid sequence shown in any one of SEQ ID NOs: 31 and 38, an LC-CDR2 comprising the amino acid sequence shown in any one of SEQ ID NOs: 42 and 45, and an LC-CDR3 comprising the amino acid sequence shown in any one of SEQ ID NOs: 60 and 64.

[0201] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 6 or a variant thereof containing up to about three (e.g., one, two, or three) amino acid substitutions; a V-CDR2 comprising the amino acid sequence set forth in any of SEQ ID NOs: 14-15 or a variant thereof containing up to about three (e.g., one, two, or three) amino acid substitutions; or a V-CDR3 comprising the amino acid sequence set forth in any of SEQ ID NOs: 23-24 or a variant thereof containing up to about three (e.g., one, two, or three) amino acid substitutions. H and V comprising an LC-CDR1 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 31 and 38 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions; an LC-CDR2 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 42 and 45 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions; and an LC-CDR3 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 60 and 64 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions. L and,

[0202] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 6, a HC-CDR2 comprising the amino acid sequence set forth in any of SEQ ID NOs: 14-15, and a HC-CDR3 comprising the amino acid sequence set forth in any of SEQ ID NOs: 23-24. H and V comprising an LC-CDR1 having an amino acid sequence shown in any one of SEQ ID NOs: 31 and 38, an LC-CDR2 having an amino acid sequence shown in any one of SEQ ID NOs: 42 and 45, and an LC-CDR3 having an amino acid sequence shown in any one of SEQ ID NOs: 60 and 64. L and,

[0203] In some embodiments, the anti-TSLP antibody comprises an HC-CDR1 comprising the amino acid sequence SEQ ID NO:6, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:14, and a V comprising the amino acid sequence SEQ ID NO:23. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO: 38, an LC-CDR2 comprising the amino acid sequence SEQ ID NO: 42, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO: 60. L or the V containing up to about five amino acid substitutions in its LC-CDRs. L and variants of

[0204] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:6, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:14, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:23. H and V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO: 38, an LC-CDR2 comprising the amino acid sequence SEQ ID NO: 42, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO: 60. L and,

[0205] In some embodiments, the anti-TSLP antibody comprises an HC-CDR1 comprising the amino acid sequence SEQ ID NO:6, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:15, and a V comprising the amino acid sequence SEQ ID NO:24. H or the V containing up to about five amino acid substitutions in its HC-CDRs. H and a variant of LC-CDR1 comprising the amino acid sequence SEQ ID NO: 31, a variant of LC-CDR2 comprising the amino acid sequence SEQ ID NO: 45, and a variant of V comprising the amino acid sequence SEQ ID NO: 64. L or the V containing up to about five amino acid substitutions in its LC-CDRs. L and variants of

[0206] In some embodiments, the anti-TSLP antibody comprises a V-CDR1 comprising the amino acid sequence SEQ ID NO:6, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:15, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:24. H and V comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO: 31, an LC-CDR2 comprising the amino acid sequence SEQ ID NO: 45, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO: 64. L and,

[0207] In some embodiments, the anti-TSLP antibody comprises a V antibody comprising the amino acid sequence set forth in SEQ ID NOs: 6, 14-15, 23-24. H , or V containing up to about five amino acid substitutions H and variants of V having the amino acid sequences shown in SEQ ID NOs: 31, 38, 42, 45, 60, and 64. L , or V containing up to about five amino acid substitutions L In some embodiments, the anti-TSLP antibody comprises a V variant comprising the amino acid sequence set forth in SEQ ID NOs: 6, 14-15, 23-24. H and V comprising the amino acid sequences set forth in SEQ ID NOs: 31, 38, 42, 45, 60, and 64. L and,

[0208] In some embodiments, the anti-TSLP antibody comprises a V antibody comprising the amino acid sequence SEQ ID NOs: 6, 14, and 23. H , or V containing up to five amino acid substitutions H and variants of V including amino acid sequences SEQ ID NOs: 38, 42 and 60 L , or V containing up to five amino acid substitutions L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NOs: 6, 14, and 23. H and V comprising the amino acid sequences SEQ ID NOs: 38, 42 and 60.L and,

[0209] In some embodiments, the anti-TSLP antibody comprises a V comprising the amino acid sequence SEQ ID NOs: 6, 15, and 24. H , or V containing up to five amino acid substitutions H and variants of V including amino acid sequences SEQ ID NOs: 31, 45 and 64. L , or V containing up to five amino acid substitutions L and V, including L In some embodiments, the anti-TSLP antibody comprises a V comprising the amino acid sequence SEQ ID NOs: 6, 15, and 24. H and V comprising the amino acid sequences SEQ ID NOs: 31, 45 and 64. L and,

[0210] In some embodiments, the anti-TSLP antibody is a V antibody having an amino acid sequence represented by any one of SEQ ID NOs: 82-83. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V represented by any one of the amino acid sequences of SEQ ID NOs: 101 to 102. L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and,

[0211] In some embodiments, the anti-TSLP antibody is V H and V H is V as shown in the amino acid sequence SEQ ID NO:82 H In some embodiments, the anti-TSLP antibody comprises one, two, or three HC-CDRs comprised in V H and V H is V as shown in the amino acid sequence SEQ ID NO:83 H and 1, 2, or 3 HC-CDRs contained in

[0212] In some embodiments, the anti-TSLP antibody is VL and V L is V as shown in the amino acid sequence SEQ ID NO:101 L In some embodiments, the anti-TSLP antibody comprises one, two, or three LC-CDRs comprised in V L and V L is V as shown in the amino acid sequence SEQ ID NO:102 L and containing one, two or three LC-CDRs contained in

[0213] In some embodiments, the anti-TSLP antibody has the amino acid sequence V as set forth in SEQ ID NO:82. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO: 101. L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L In some embodiments, the anti-TSLP antibody comprises the V sequence set forth in the amino acid sequence SEQ ID NO:83. H V containing HC-CDR1, HC-CDR2 and HC-CDR3 contained in H and V, as shown in the amino acid sequence SEQ ID NO: 102. L V containing LC-CDR1, LC-CDR2, and LC-CDR3 contained in L and,

[0214] In some embodiments, the anti-TSLP antibody comprises a V antibody comprising an amino acid sequence set forth in any of SEQ ID NOs: 82-83. H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to any of the amino acid sequences of SEQ ID NOs: 82 to 83. H and a V having any one of the amino acid sequences of SEQ ID NOs: 101 to 102. Lor a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO: 101-102. L In some embodiments, the anti-TSLP antibody comprises a V variant comprising an amino acid sequence set forth in any of SEQ ID NOs: 82-83. H and V comprising an amino acid sequence represented by any one of SEQ ID NOs: 101 to 102. L and,

[0215] In some embodiments, the anti-TSLP antibody comprises a V polypeptide comprising the amino acid sequence SEQ ID NO:82. H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 82. H and a variant of V comprising the amino acid sequence SEQ ID NO:101. L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 101. L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NO:82. H and V comprising the amino acid sequence SEQ ID NO:101 L and,

[0216] In some embodiments, the anti-TSLP antibody comprises a V polypeptide comprising the amino acid sequence SEQ ID NO:83. H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 83. H and a variant of V comprising the amino acid sequence SEQ ID NO: 102. Lor a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 102. L In some embodiments, the anti-TSLP antibody comprises a variant of V comprising the amino acid sequence SEQ ID NO:83. H and V comprising the amino acid sequence SEQ ID NO: 102 L and,

[0217] In some embodiments, functional epitopes can be analyzed by combinatorial alanine scanning. In this process, combinatorial alanine scanning can be used to identify amino acids in the TSLP protein that are required for interaction with an anti-TSLP antibody. In some embodiments, the epitope is conformational, and thus, the epitope can be identified using a crystal structure of an anti-TSLP antibody bound to the TSLP protein.

[0218] In some embodiments, the amino acid substitutions are limited to only the "exemplary substitutions" shown in Table 4 herein. In some embodiments, the amino acid substitutions are limited to only the "preferred substitutions" shown in Table 4 herein.

[0219] In some embodiments, the present application provides antibodies that compete with any of the anti-TSLP antibodies described herein for binding to TSLP. In some embodiments, the present application provides antibodies that can compete with any of the anti-TSLP antibodies described herein for binding to an epitope on TSLP. In some embodiments, the present application provides antibodies that can compete with any of the anti-TSLP antibodies described herein for binding to an epitope on TSLP. H and V L and an anti-TSLP antibody that binds to the same epitope as an anti-TSLP antibody molecule comprising: H comprises an amino acid sequence represented by any one of SEQ ID NOs: 65 to 83, L In some embodiments, the binding to TSLP is determined by V H and VL and an anti-TSLP antibody that competes with an anti-TSLP antibody comprising: H comprises an amino acid sequence represented by any one of SEQ ID NOs: 65 to 83, L comprises an amino acid sequence represented by any one of SEQ ID NOs: 84 to 102.

[0220] In some embodiments, competition experiments can be used to identify monoclonal antibodies that compete with the anti-TSLP antibodies described herein for binding to TSLP. Competition experiments can determine whether two antibodies bind to the same epitope by recognizing the same or spatially overlapping epitopes, or by competitively inhibiting the binding of one antibody to the antigen with another. In some embodiments, such competing antibodies bind to the same epitope as the antibodies described herein. Some exemplary competition experiments include, but are not limited to, the routine experiments described in, for example, Harlow and Lane (1988) Antibodies: A Laboratory Manual, ch. 14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY). Detailed exemplary methods for analyzing epitopes for antibody binding are described in Morris (1996) "Epitope Mapping Protocols," in Methods in Molecular Biology, vol. 66 (Humana Press, Totowa, NJ). In some embodiments, antibodies are said to bind to the same epitope if each antibody blocks the binding of the other antibody by 50% or more. In some embodiments, antibodies that compete with anti-TSLP antibodies herein are chimeric, humanized, or fully human.

[0221] The sequences of exemplary anti-TSLP antibodies are shown in Tables 2 and 3, where the CDRs are numbered according to the Kabat definition. Those skilled in the art will recognize that there are many known algorithms (Kabat definitions) for predicting the locations of CDRs and defining antibody light and heavy chain variable regions. The CDRs of the anti-TSLP antibodies described herein are numbered according to the Kabat definition. H and / or V L Antibodies other than the examples shown in the table below that contain sequences but based on predictive algorithms are also included within the scope of this application.

[0222] [Table 2-1]

[0223] [Table 2-2]

[0224] [Table 2-3]

[0225] [Table 2-4]

[0226] [Table 2-5]

[0227] [Table 3-1]

[0228] [Table 3-2]

[0229] [Table 3-3]

[0230] [Table 3-4]

[0231] [Table 3-5]

[0232] TSLP TSLP is an epithelial cell-derived cytokine constitutively expressed in the skin, intestine, lung, and thymus (He R, et al., Ann NY Acad Sci 2010;1183:13-24). Here, TSLP expression levels are highest in lung- and skin-derived epithelial cells (Ziegler SF, Curr Opin Immunol 2010;22:795-799). TSLP was first identified in the supernatant of the mouse thymic stromal cell line Z210R.1 as a distant homolog of IL-7. Subsequent expression cloning demonstrated that murine TSLP (mTSLP) is a member of the hematopoietic cytokine family (Sims JE, et al., J ExpMed 2000;192:671-680). Sequence prediction indicates that this cytokine resembles a four-helical structure, with two N-glycosylation sites and six cysteine ​​residues (Kashyap M, et al., J Immunol 2011;187:1207-1211). Human TSLP (hTSLP) and mTSLP exhibit low homology, sharing only 43% amino acid identity (Reche PA, et al., J Immunol 2001;167:336-343; Quentmeier H, et al., Leukemia 2001;15:1286-1292).

[0233] Two isoforms of TSLP, short and long, have been described in mice, but the functional consequences of these variants remain unclear. In humans, the short TSLP is the predominant isoform expressed under basal conditions, while the long TSLP is elevated under inflammatory conditions (Fornasa G, et al., J Allergy Clin Immunol 2015;136:413-22; Tsilingiri K, et al., CellMol Gastroenterol Hepatol 2017;3:174-82). Furthermore, evidence suggests that TSLP can be cleaved by several endogenous proteases under pathological conditions (Poposki JA, et al., J Allergy Clin Immunol 2017;139:1559-67.e8; Nagarkar DR, et al., J Allergy Clin Immunol 2013;132:593-600.e12). For example, furin, which is elevated in biopsies from patients with celiac disease, can cleave the long form of TSLP, producing 10 kDa and 4 kDa fragments in human peripheral blood mononuclear cells, and these fragments have different activities compared to mature TSLP (Biancheri P, et al., Gut 2016, 65:1670-80).

[0234] TSLP induces innate allergic immune responses by targeting mDCs, mast cells, eosinophils, basophils, and NKT cells (Al-Shami A, et al., J ExpMed 2004;200:159-168; Wu WH, et al., J Allergy Clin Immunol 2010;126:290-299, 299.e1-e4; Soumelis V, et al., Nat Immunol 2002;3:673-680). TSLP significantly upregulates the expression of MHC class II, CD54, CD80, CD83, CD86, and DC-lamp on mDCs (Liu YJ, J ExpMed 2006;203:269-273). Furthermore, unlike CD40L and Toll-like receptor (TLR) ligands, TSLP does not stimulate mDCs to produce Th1-polarizing cytokines (IL-12 and type 1 interferon) or pro-inflammatory cytokines (TNFα, IL-1β, and IL-6).

[0235] Recent evidence indicates that TSLP plays an important role in the pathology of allergic asthma and atopic dermatitis (AD). It is compelling to highlight TSLP as a potential therapeutic approach for allergic diseases. Further analysis of the mechanisms underlying the TSLP-mediated Th2 phenotype immune response will provide new insights into this quest. TSLP also contributes to the creation of a Th2-permissive microenvironment, further promoting the development of asthma (Willart MA, et al., Allergol Int 2010, 59:95-103).

[0236] TSLP receptor (TSLPR) The TSLP receptor (TSLPR) complex consists of TSLPR and IL-7 receptor α (IL-7R) (Park LS, et al., J Exp Med 2000;192:659-670). TSLP exerts its biological activity across a wide range of cell types by binding to an isodimeric receptor composed of the IL-7 receptor α chain (IL-7Rα) and the TSLPR chain closely associated with the common receptor γ chain (γc). While TSLPR alone has low affinity for TSLP, binding of TSLPR to IL-7Ra creates a single high-affinity binding site for TSLP and triggers signal transduction (He R, et al., Ann NY Acad Sci 2010;1183:13-24). Binding of TSLPR to the IL-7Rα chain results in high-affinity binding and activation of signal transducer and activator of transcription 3 (STAT3) and 5 (STAT5) (Pandey A, et al., Nat Immunol 2000, 1:59-64). Expression of TSLPR transcripts can be detected in early B- and T-cell progenitors, peripheral CD4+ T cells, mast cells, and DCs of two species (He SH, et al., Clin Exp Immunol 2011, 165:29-37).

[0237] Therefore, neutralizing the binding of TSLP to TSLPR is a therapeutic approach to treating diseases and conditions mediated by TSLP signaling.

[0238] Full-length anti-TSLP antibody In some embodiments, the anti-TSLP antibody is a full-length anti-TSLP antibody. In some embodiments, the full-length anti-TSLP antibody is IgA, IgD, IgE, IgG, or IgM. In some embodiments, the full-length anti-TSLP antibody comprises an IgG constant region domain, such as the constant region domain of IgG1, IgG2, IgG3, IgG4, or a variant thereof. In some embodiments, the full-length anti-TSLP antibody comprises a lambda light chain constant region. In some embodiments, the full-length anti-TSLP antibody comprises a kappa light chain constant region. In some embodiments, the full-length anti-TSLP antibody is a full-length human anti-TSLP antibody. In some embodiments, the full-length anti-TSLP antibody comprises a mouse immunoglobulin Fc sequence. In some embodiments, the full-length anti-TSLP antibody comprises an altered or otherwise modified Fc sequence to provide enhanced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) effects.

[0239] Thus, for example, in some embodiments, a full-length anti-TSLP antibody comprising an IgG1 constant region is provided, wherein the anti-TSLP antibody specifically binds to TSLP. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0240] In some embodiments, a full-length anti-TSLP antibody is provided that comprises an IgG2 constant region, wherein the anti-TSLP antibody specifically binds to TSLP. In some embodiments, the IgG2 is human IgG2. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0241] In some embodiments, a full-length anti-TSLP antibody is provided that comprises an IgG3 constant region, wherein the anti-TSLP antibody specifically binds to TSLP. In some embodiments, the IgG3 is human IgG3. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0242] In some embodiments, a full-length anti-TSLP antibody is provided that comprises an IgG4 constant region, wherein the anti-TSLP antibody specifically binds to TSLP. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0243] In some embodiments, a full-length anti-TSLP antibody comprising an IgG1 constant region is provided, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising the amino acid sequence set forth in any of SEQ ID NOs: 1-6 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions; an HC-CDR2 comprising the amino acid sequence set forth in any of SEQ ID NOs: 7-15 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions; and an HC-CDR3 comprising the amino acid sequence set forth in any of SEQ ID NOs: 16-24 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions; and b) an LC-CDR1 comprising the amino acid sequence set forth in any of SEQ ID NOs: 25-38 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions. and a light chain variable domain comprising an LC-CDR2 comprising the amino acid sequence set forth in any of SEQ ID NOs:39 to 49 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions, and an LC-CDR3 comprising the amino acid sequence set forth in any of SEQ ID NOs:50 to 64 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126.In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0244] In some embodiments, a full-length anti-TSLP antibody comprising an IgG2 constant region is provided, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising the amino acid sequence set forth in any of SEQ ID NOs: 1-6 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions; an HC-CDR2 comprising the amino acid sequence set forth in any of SEQ ID NOs: 7-15 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions; and an HC-CDR3 comprising the amino acid sequence set forth in any of SEQ ID NOs: 16-24 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions; and b) an LC-CDR1 comprising the amino acid sequence set forth in any of SEQ ID NOs: 25-38 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions. and a light chain variable domain comprising an LC-CDR2 comprising the amino acid sequence set forth in any of SEQ ID NOs: 39 to 49 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions, and an LC-CDR3 comprising the amino acid sequence set forth in any of SEQ ID NOs: 50 to 64 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions. In some embodiments, the IgG2 is human IgG2. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0245] In some embodiments, a full-length anti-TSLP antibody comprising an IgG3 constant region is provided, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising the amino acid sequence set forth in any of SEQ ID NOs: 1-6 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions; an HC-CDR2 comprising the amino acid sequence set forth in any of SEQ ID NOs: 7-15 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions; and an HC-CDR3 comprising the amino acid sequence set forth in any of SEQ ID NOs: 16-24 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions; and b) an LC-CDR1 comprising the amino acid sequence set forth in any of SEQ ID NOs: 25-38 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions. and a light chain variable domain comprising an LC-CDR2 comprising the amino acid sequence set forth in any of SEQ ID NOs: 39 to 49 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions, and an LC-CDR3 comprising the amino acid sequence set forth in any of SEQ ID NOs: 50 to 64 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions. In some embodiments, the IgG3 is a human IgG3. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0246] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising the amino acid sequence set forth in any of SEQ ID NOs: 1-6 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions; an HC-CDR2 comprising the amino acid sequence set forth in any of SEQ ID NOs: 7-15 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions; and an HC-CDR3 comprising the amino acid sequence set forth in any of SEQ ID NOs: 16-24 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions; and b) an LC-CDR1 comprising the amino acid sequence set forth in any of SEQ ID NOs: 25-38 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions. and a light chain variable domain comprising an LC-CDR2 comprising the amino acid sequence set forth in any of SEQ ID NOs:39 to 49 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions, and an LC-CDR3 comprising the amino acid sequence set forth in any of SEQ ID NOs:50 to 64 or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126.In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0247] In some embodiments, a full-length anti-TSLP antibody comprising an IgG1 constant region is provided, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence set forth in any of SEQ ID NOs: 1-6, an HC-CDR2 comprising the amino acid sequence set forth in any of SEQ ID NOs: 7-15, and an HC-CDR3 comprising the amino acid sequence set forth in any of SEQ ID NOs: 16-24, or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions in the HC-CDR sequence; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence set forth in any of SEQ ID NOs: 25-38, an LC-CDR2 comprising the amino acid sequence set forth in any of SEQ ID NOs: 39-49, and an LC-CDR3 comprising the amino acid sequence set forth in any of SEQ ID NOs: 50-64, or a variant thereof comprising up to about three (e.g., one, two, or three) amino acid substitutions in the HC-CDR sequence. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0248] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence set forth in any of SEQ ID NOs: 1-6, an HC-CDR2 comprising the amino acid sequence set forth in any of SEQ ID NOs: 7-15, and an HC-CDR3 comprising the amino acid sequence set forth in any of SEQ ID NOs: 16-24, or a variant thereof in which the HC-CDR sequence contains up to about three (e.g., one, two, or three) amino acid substitutions; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence set forth in any of SEQ ID NOs: 25-38, an LC-CDR2 comprising the amino acid sequence set forth in any of SEQ ID NOs: 39-49, and an LC-CDR3 comprising the amino acid sequence set forth in any of SEQ ID NOs: 50-64, or a variant thereof in which the HC-CDR sequence contains up to about three (e.g., one, two, or three) amino acid substitutions. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0249] In some embodiments, a full-length anti-TSLP antibody comprising an IgG1 constant region is provided, wherein the anti-TSLP antibody comprises: (a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence set forth in any of SEQ ID NOs: 1 to 6, an HC-CDR2 comprising the amino acid sequence set forth in any of SEQ ID NOs: 7 to 15, and an HC-CDR3 comprising the amino acid sequence set forth in any of SEQ ID NOs: 16 to 24; and (b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence set forth in any of SEQ ID NOs: 25 to 38, an LC-CDR2 comprising the amino acid sequence set forth in any of SEQ ID NOs: 39 to 49, and an LC-CDR3 comprising the amino acid sequence set forth in any of SEQ ID NOs: 50 to 64. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0250] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises: (a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence set forth in any of SEQ ID NOs: 1 to 6, an HC-CDR2 comprising the amino acid sequence set forth in any of SEQ ID NOs: 7 to 15, and an HC-CDR3 comprising the amino acid sequence set forth in any of SEQ ID NOs: 16 to 24; and (b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence set forth in any of SEQ ID NOs: 25 to 38, an LC-CDR2 comprising the amino acid sequence set forth in any of SEQ ID NOs: 39 to 49, and an LC-CDR3 comprising the amino acid sequence set forth in any of SEQ ID NOs: 50 to 64. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0251] In some embodiments, a full-length anti-TSLP antibody is provided comprising an IgG1 constant region, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:1, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:7, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:16; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:25, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:39, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:50. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0252] In some embodiments, a full-length anti-TSLP antibody is provided comprising an IgG1 constant region, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:1, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:8, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:16; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:25, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:39, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:51. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0253] In some embodiments, a full-length anti-TSLP antibody is provided comprising an IgG1 constant region, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:1, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:8, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:17; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:26, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:40, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:52. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0254] In some embodiments, a full-length anti-TSLP antibody is provided comprising an IgG1 constant region, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:1, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:8, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:16; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:27, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:41, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:52. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0255] In some embodiments, a full-length anti-TSLP antibody is provided comprising an IgG1 constant region, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:1, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:9, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:16; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:28, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:39, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:52. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0256] In some embodiments, a full-length anti-TSLP antibody is provided comprising an IgG1 constant region, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:1, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:8, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:18; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:27, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:39, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:53. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0257] In some embodiments, a full-length anti-TSLP antibody is provided comprising an IgG1 constant region, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:2, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:10, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:19; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:29, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:42, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:54. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0258] In some embodiments, a full-length anti-TSLP antibody is provided comprising an IgG1 constant region, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:2, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:10, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:19; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:30, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:43, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:55. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0259] In some embodiments, a full-length anti-TSLP antibody is provided comprising an IgG1 constant region, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:2, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:10, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:19; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:31, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:44, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:56. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0260] In some embodiments, a full-length anti-TSLP antibody is provided comprising an IgG1 constant region, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:2, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:10, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:19; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:32, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:45, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:57. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0261] In some embodiments, a full-length anti-TSLP antibody is provided comprising an IgG1 constant region, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:3, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:11, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:19; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:33, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:45, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:58. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0262] In some embodiments, a full-length anti-TSLP antibody is provided comprising an IgG1 constant region, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:3, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:10, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:19; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:31, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:46, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:59. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0263] In some embodiments, a full-length anti-TSLP antibody is provided comprising an IgG1 constant region, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:3, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:12, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:20; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:34, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:47, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:60. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0264] In some embodiments, a full-length anti-TSLP antibody is provided comprising an IgG1 constant region, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:4, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:13, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:21; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:35, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:48, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:61. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0265] In some embodiments, a full-length anti-TSLP antibody is provided comprising an IgG1 constant region, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:4, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:13, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:22; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:36, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:48, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:62. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0266] In some embodiments, a full-length anti-TSLP antibody is provided comprising an IgG1 constant region, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:5, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:13, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:22; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:37, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:49, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:63. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0267] In some embodiments, a full-length anti-TSLP antibody is provided comprising an IgG1 constant region, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:6, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:14, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:23; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:38, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:42, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:60. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0268] In some embodiments, a full-length anti-TSLP antibody is provided comprising an IgG1 constant region, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:6, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:15, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:24; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:31, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:45, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:64. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0269] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:1, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:7, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:16; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:25, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:39, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:50. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0270] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:1, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:8, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:16; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:25, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:39, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:51. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0271] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:1, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:8, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:17; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:26, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:40, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:52. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0272] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:1, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:8, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:16; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:27, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:41, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:52. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0273] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:1, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:9, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:16; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:28, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:39, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:52. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0274] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:1, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:8, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:18; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:27, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:39, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:53. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0275] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:2, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:10, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:19; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:29, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:42, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:54. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0276] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:2, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:10, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:19; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:30, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:43, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:55. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0277] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:2, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:10, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:19; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:31, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:44, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:56. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0278] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:2, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:10, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:19; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:32, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:45, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:57. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0279] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:3, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:11, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:19; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:33, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:45, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:58. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0280] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:3, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:10, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:19; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:31, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:46, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:59. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0281] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:3, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:12, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:20; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:34, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:47, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:60. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0282] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:4, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:13, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:21; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:35, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:48, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:61. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0283] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:4, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:13, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:22; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:36, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:48, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:62. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0284] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:5, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:13, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:22; and b) a heavy chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:37, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:49, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:63. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0285] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:6, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:14, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:23; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:38, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:42, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:60. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0286] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises: a) a heavy chain variable domain comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:6, an HC-CDR2 comprising the amino acid sequence SEQ ID NO:15, and an HC-CDR3 comprising the amino acid sequence SEQ ID NO:24; and b) a light chain variable domain comprising an LC-CDR1 comprising the amino acid sequence SEQ ID NO:31, an LC-CDR2 comprising the amino acid sequence SEQ ID NO:45, and an LC-CDR3 comprising the amino acid sequence SEQ ID NO:64. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 125, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0287] In some embodiments, a full-length anti-TSLP antibody is provided that comprises an IgG1 constant region, wherein the anti-TSLP antibody comprises a heavy chain variable domain V comprising an amino acid sequence set forth in any of SEQ ID NOs: 65 to 83. H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to any of the amino acid sequences of SEQ ID NOs: 65 to 83. Hand a light chain variable domain V comprising an amino acid sequence represented by any one of SEQ ID NOs: 84 to 102. L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 84-102. L and a variant of SEQ ID NO:126. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0288] In some embodiments, a full-length anti-TSLP antibody is provided that comprises an IgG2 constant region, wherein the anti-TSLP antibody comprises a heavy chain variable domain V comprising an amino acid sequence set forth in any of SEQ ID NOs: 65 to 83. H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to any of the amino acid sequences of SEQ ID NOs: 65 to 83. H and a light chain variable domain V comprising an amino acid sequence represented by any one of SEQ ID NOs: 84 to 102. Lor a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 84-102. L and a variant of SEQ ID NO: 127. In some embodiments, the IgG2 is human IgG2. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0289] In some embodiments, a full-length anti-TSLP antibody is provided that comprises an IgG3 constant region, wherein the anti-TSLP antibody comprises a heavy chain variable domain V comprising an amino acid sequence set forth in any of SEQ ID NOs: 65 to 83. H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to any of the amino acid sequences of SEQ ID NOs: 65 to 83. H and a light chain variable domain V comprising an amino acid sequence represented by any one of SEQ ID NOs: 84 to 102. L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 84-102. L and a variant of SEQ ID NO: 127. In some embodiments, the IgG3 is a human IgG3. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO: 127.

[0290] In some embodiments, a full-length anti-TSLP antibody is provided that comprises an IgG4 constant region, wherein the anti-TSLP antibody comprises a heavy chain variable domain V comprising an amino acid sequence set forth in any of SEQ ID NOs: 65 to 83. H or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to any of the amino acid sequences of SEQ ID NOs: 65 to 83. H and a light chain variable domain V comprising an amino acid sequence represented by any one of SEQ ID NOs: 84 to 102. L or a V having at least about 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence SEQ ID NO: 84-102. L and a variant of SEQ ID NO:126. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0291] In some embodiments, a full-length anti-TSLP antibody is provided that comprises an IgG1 constant region, wherein the anti-TSLP antibody comprises a heavy chain variable domain V comprising an amino acid sequence set forth in any of SEQ ID NOs: 65 to 83. Hand a light chain variable domain V comprising an amino acid sequence represented by any one of SEQ ID NOs: 84 to 102. L and. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0292] In some embodiments, a full-length anti-TSLP antibody is provided that comprises an IgG4 constant region, wherein the anti-TSLP antibody comprises a heavy chain variable domain V comprising an amino acid sequence set forth in any of SEQ ID NOs: 65 to 83. H and a light chain variable domain V comprising an amino acid sequence represented by any one of SEQ ID NOs: 84 to 102. Land. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0293] In some embodiments, a full-length anti-TSLP antibody is provided that comprises an IgG1 constant region, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:65 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:84. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0294] In some embodiments, a full-length anti-TSLP antibody comprising an IgG1 constant region is provided, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:65 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:85. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0295] In some embodiments, a full-length anti-TSLP antibody is provided that comprises an IgG1 constant region, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:66 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:84. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0296] In some embodiments, a full-length anti-TSLP antibody comprising an IgG1 constant region is provided, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:66 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:85. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0297] In some embodiments, a full-length anti-TSLP antibody is provided that comprises an IgG1 constant region, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:67 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:84. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0298] In some embodiments, a full-length anti-TSLP antibody comprising an IgG1 constant region is provided, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:67 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:85. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0299] In some embodiments, a full-length anti-TSLP antibody is provided that comprises an IgG1 constant region, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:68 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:84. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0300] In some embodiments, a full-length anti-TSLP antibody comprising an IgG1 constant region is provided, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:68 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:85. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0301] In some embodiments, a full-length anti-TSLP antibody is provided that comprises an IgG1 constant region, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:69 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:86. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0302] In some embodiments, a full-length anti-TSLP antibody comprising an IgG1 constant region is provided, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:70 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:87. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0303] In some embodiments, a full-length anti-TSLP antibody comprising an IgG1 constant region is provided, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:69 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:88. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124, and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0304] In some embodiments, a full-length anti-TSLP antibody comprising an IgG1 constant region is provided, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:71 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:89. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0305] In some embodiments, a full-length anti-TSLP antibody is provided that comprises an IgG1 constant region, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:72 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:90. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0306] In some embodiments, a full-length anti-TSLP antibody is provided that comprises an IgG1 constant region, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:73 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:91. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0307] In some embodiments, a full-length anti-TSLP antibody is provided that comprises an IgG1 constant region, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:74 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:91. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0308] In some embodiments, a full-length anti-TSLP antibody comprising an IgG1 constant region is provided, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:75 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:91. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0309] In some embodiments, a full-length anti-TSLP antibody is provided that comprises an IgG1 constant region, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:73 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:92. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0310] In some embodiments, a full-length anti-TSLP antibody is provided that comprises an IgG1 constant region, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:73 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:93. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0311] In some embodiments, a full-length anti-TSLP antibody is provided that comprises an IgG1 constant region, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:73 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:94. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0312] In some embodiments, a full-length anti-TSLP antibody comprising an IgG1 constant region is provided, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:76 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:95. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0313] In some embodiments, a full-length anti-TSLP antibody is provided that comprises an IgG1 constant region, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:77 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:96. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0314] In some embodiments, a full-length anti-TSLP antibody comprising an IgG1 constant region is provided, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:78 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:97. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0315] In some embodiments, a full-length anti-TSLP antibody is provided that comprises an IgG1 constant region, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:79 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:98. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0316] In some embodiments, a full-length anti-TSLP antibody comprising an IgG1 constant region is provided, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:80 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:99. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0317] In some embodiments, a full-length anti-TSLP antibody comprising an IgG1 constant region is provided, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:81 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:100. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0318] In some embodiments, a full-length anti-TSLP antibody comprising an IgG1 constant region is provided, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:82 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:101. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0319] In some embodiments, a full-length anti-TSLP antibody comprising an IgG1 constant region is provided, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:83 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:102. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:124 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0320] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:65 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:84. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0321] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:65 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:85. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0322] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:66 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:84. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0323] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:66 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:85. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0324] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:67 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:84. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0325] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:67 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:85. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0326] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:68 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:84. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0327] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:68 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:85. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0328] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:69 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:86. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0329] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:70 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:87. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0330] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:69 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:88. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0331] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:71 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:89. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0332] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:72 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:90. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0333] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:73 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:91. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0334] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:74 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:91. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0335] In some embodiments, a full-length anti-TSLP antibody comprising an IgG4 constant region is provided, wherein the anti-TSLP antibody comprises a heavy chain variable domain comprising the amino acid sequence SEQ ID NO:75 and a light chain variable domain comprising the amino acid sequence SEQ ID NO:91. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:126. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence SEQ ID NO:125 and the light chain constant region comprises or consists of the amino acid sequence SEQ ID NO:127.

[0336] In some embodiments, a full-l...

Claims

1. (i) a V-CDR1 comprising the amino acid sequence SEQ ID NO:1, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:7, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:16; Ｈ and a V-CDR1 comprising the amino acid sequence SEQ ID NO: 25, a LC-CDR2 comprising the amino acid sequence SEQ ID NO: 39, and a LC-CDR3 comprising the amino acid sequence SEQ ID NO:

50. Ｌ , (ii) a V-CDR1 comprising the amino acid sequence SEQ ID NO:1, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:8, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:16; Ｈ and a V-CDR1 comprising the amino acid sequence SEQ ID NO: 25, a LC-CDR2 comprising the amino acid sequence SEQ ID NO: 39, and a LC-CDR3 comprising the amino acid sequence SEQ ID NO:

51. Ｌ , (iii) a V-CDR1 comprising the amino acid sequence SEQ ID NO:1, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:8, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:17; Ｈ and a V-CDR1 comprising the amino acid sequence SEQ ID NO: 26, a LC-CDR2 comprising the amino acid sequence SEQ ID NO: 40, and a LC-CDR3 comprising the amino acid sequence SEQ ID NO:

52. Ｌ , (iv) a V-CDR1 comprising the amino acid sequence SEQ ID NO:1, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:8, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:16; Ｈ and a V-CDR1 comprising the amino acid sequence SEQ ID NO: 27, a LC-CDR2 comprising the amino acid sequence SEQ ID NO: 41, and a LC-CDR3 comprising the amino acid sequence SEQ ID NO:

52. Ｌ , (v) V comprising an HC-CDR1 having the amino acid sequence SEQ ID NO: 1, an HC-CDR2 having the amino acid sequence SEQ ID NO: 9, and an HC-CDR3 having the amino acid sequence SEQ ID NO:

16. Ｈ and a V-CDR1 comprising the amino acid sequence SEQ ID NO: 28, a LC-CDR2 comprising the amino acid sequence SEQ ID NO: 39, and a LC-CDR3 comprising the amino acid sequence SEQ ID NO:

52. Ｌ ,or (vi) a V-CDR1 comprising the amino acid sequence SEQ ID NO:1, a HC-CDR2 comprising the amino acid sequence SEQ ID NO:8, and a HC-CDR3 comprising the amino acid sequence SEQ ID NO:18; Ｈ and a V-CDR1 comprising the amino acid sequence SEQ ID NO: 27, a LC-CDR2 comprising the amino acid sequence SEQ ID NO: 39, and a LC-CDR3 comprising the amino acid sequence SEQ ID NO:

53. Ｌ Including, Isolated anti-TSLP antibodies.

2. (i) V comprising the amino acid sequence SEQ ID NO:65 Ｈ or a V having at least 90% sequence identity with the amino acid sequence SEQ ID NO: 65 Ｈ and a variant of V comprising the amino acid sequence SEQ ID NO:

84. Ｌ or a V having at least 90% sequence identity with the amino acid sequence SEQ ID NO: 84 Ｌ and mutants of (ii) V comprising the amino acid sequence SEQ ID NO:65 Ｈ or a V having at least 90% sequence identity with the amino acid sequence SEQ ID NO: 65 Ｈ and a variant of V comprising the amino acid sequence SEQ ID NO:

85. Ｌ or a V having at least 90% sequence identity with the amino acid sequence SEQ ID NO: 85 Ｌ and mutants of (iii) V comprising the amino acid sequence SEQ ID NO:66 Ｈ or a V having at least 90% sequence identity with the amino acid sequence SEQ ID NO: 66 Ｈ and a variant of V comprising the amino acid sequence SEQ ID NO:

84. Ｌ or a V having at least 90% sequence identity with the amino acid sequence SEQ ID NO: 84 Ｌ and mutants of (iv) V comprising the amino acid sequence SEQ ID NO:66 Ｈ or a V having at least 90% sequence identity with the amino acid sequence SEQ ID NO: 66 Ｈ and a variant of V comprising the amino acid sequence SEQ ID NO:

85. Ｌ or a V having at least 90% sequence identity with the amino acid sequence SEQ ID NO: 85 Ｌ and mutants of (v) V comprising the amino acid sequence SEQ ID NO:67 Ｈ or a V having at least 90% sequence identity with the amino acid sequence SEQ ID NO: 67 Ｈ and a variant of V comprising the amino acid sequence SEQ ID NO:

84. Ｌ or a V having at least 90% sequence identity with the amino acid sequence SEQ ID NO: 84 Ｌ and mutants of (vi) V comprising the amino acid sequence SEQ ID NO:67 Ｈ or a V having at least 90% sequence identity with the amino acid sequence SEQ ID NO: 67 Ｈ and a variant of V comprising the amino acid sequence SEQ ID NO:

85. Ｌ or a V having at least 90% sequence identity with the amino acid sequence SEQ ID NO: 85 Ｌ and mutants of (vii) V comprising the amino acid sequence SEQ ID NO:68 Ｈ or a V having at least 90% sequence identity with the amino acid sequence SEQ ID NO: 68 Ｈ and a variant of V comprising the amino acid sequence SEQ ID NO:

84. Ｌ or a V having at least 90% sequence identity with the amino acid sequence SEQ ID NO: 84 Ｌ and mutants of (viii) V comprising the amino acid sequence SEQ ID NO:68 Ｈ or a V having at least 90% sequence identity with the amino acid sequence SEQ ID NO: 68 Ｈ and a variant of V comprising the amino acid sequence SEQ ID NO:

85. Ｌ or a V having at least 90% sequence identity with the amino acid sequence SEQ ID NO: 85 Ｌ and mutants of (ix) V comprising the amino acid sequence SEQ ID NO:69 Ｈ or a V having at least 90% sequence identity with the amino acid sequence SEQ ID NO:69 Ｈ and a variant of V comprising the amino acid sequence SEQ ID NO:

86. Ｌ or a V having at least 90% sequence identity with the amino acid sequence SEQ ID NO: 86 Ｌ and mutants of (x) V comprising the amino acid sequence SEQ ID NO:70 Ｈ or a V having at least 90% sequence identity with the amino acid sequence SEQ ID NO: 70 Ｈ and a variant of V comprising the amino acid sequence SEQ ID NO:

87. Ｌ or a V having at least 90% sequence identity with the amino acid sequence SEQ ID NO: 87 Ｌ and mutants of (xi) V comprising the amino acid sequence SEQ ID NO:69 Ｈ or a V having at least 90% sequence identity with the amino acid sequence SEQ ID NO:69 Ｈ and a variant of V comprising the amino acid sequence SEQ ID NO:

88. Ｌ or a V having at least 90% sequence identity with the amino acid sequence SEQ ID NO: 88 Ｌ and mutants of (xii) V comprising the amino acid sequence SEQ ID NO:71 Ｈ or a V having at least 90% sequence identity with the amino acid sequence SEQ ID NO: 71 Ｈ and a variant of V comprising the amino acid sequence SEQ ID NO:

89. Ｌ or a V having at least 90% sequence identity with the amino acid sequence SEQ ID NO: 89 Ｌ with a variant of, or (xiii) V comprising the amino acid sequence SEQ ID NO:72 Ｈ or a V having at least 90% sequence identity with the amino acid sequence SEQ ID NO: 72 Ｈ and a variant of V comprising the amino acid sequence SEQ ID NO:

90. Ｌ or a V having at least 90% sequence identity with the amino acid sequence SEQ ID NO:90 Ｌ and a variant of 2. The isolated anti-TSLP antibody of claim 1.

3. 3. An isolated anti-TSLP antibody according to claim 1 or 2, The anti-TSLP antibody comprises an Fc fragment. Isolated anti-TSLP antibodies.

4. A gene encoding an anti-TSLP antibody according to any one of claims 1 to 3, Isolated nucleic acid molecule.

5. 5. The isolated nucleic acid molecule of claim 4. vector.

6. 5. The isolated anti-TSLP antibody of claim 1, the nucleic acid molecule of claim 2, or the vector of claim 3. Isolated host cells.

7. a) culturing the isolated host cell of claim 6 under conditions allowing effective expression of an anti-TSLP antibody; b) obtaining the expressed anti-TSLP antibody from the host cell; Methods for preparing anti-TSLP antibodies.

8. 7. An isolated anti-TSLP antibody according to any one of claims 1 to 3, a nucleic acid molecule according to claim 4, a vector according to claim 5 or an isolated host cell according to claim 6, and a pharma- ceutical acceptable vector. Pharmaceutical compositions.

9. 13. Use of an isolated anti-TSLP antibody according to any one of claims 1 to 3, a nucleic acid molecule according to claim 4, a vector according to claim 5, or an isolated host cell according to claim 6 in the manufacture of a therapeutic agent for treating a disease or condition, comprising The disease or condition is associated with TSLP signaling and includes an inflammatory or autoimmune disease or condition; Preferably, the disease or condition is selected from asthma, idiopathic pulmonary fibrosis, atopic dermatitis, allergic conjunctivitis, allergic rhinitis, Netherton's syndrome, eosinophilic esophagitis (EoE), food allergy, allergic diarrhea, eosinophilic gastroenteritis, allergic bronchopulmonary aspergillosis (ABPA), allergic fungal sinusitis, cancer, rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), systemic sclerosis, keloids, ulcerative colitis, chronic rhino-sinusitis (CRS), nasal polyps, chronic eosinophilic pneumonitis, eosinophilic bronchitis, celiac disease, Churg-Strauss syndrome, eosinophilic myalgia syndrome, hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis, and inflammatory bowel disease; use.

Images